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Abstract  
Serotonin (5-HT) is a neurotransmitter that is mainly expressed in brain where 
serves a wide array of physiological and behavioural functions. Literature 
described that some mediators of inflammation (i.e. cytokines) have been 
implicated in the modulation of monoaminergic response and this may be 
associated with pathophysiology of depression and in the responsiveness of 
antidepressant treatment in both humans and animals (Capuron and Miller, 
2011). A hypothesis suggests that cytokines may affect the serotonergic system 
through p38 MAP kinase dependent mechanisms particularly at the serotonin 
transporters (Zhu et al., 2006) and 5HT7 receptors (Lieb et al., 2005; Mahe et 
al., 2005). The aim of this study was to show the interaction of Interleukin 1β 
(IL-1β) or p38 MAP kinase on serotonin transporter (SERT) and 5HT7 receptors 
in cells lines and native tissue, highlighting the biochemical mechanism of this 
system. The IL-1β and p38 MAP kinase activator, anisomycin, did not show any 
effect on 5-HT uptake and p38 MAPK activation in rodent native brain tissue, in 
human platelets and in cell lines in contrast to literature reports (Zhu et al., 
2010).  A different method was then used in which a release of cytokines was 
induced directly in the rat brain through an i.c.v. LPS treatment. Although pro-
inflammatory cytokines involved in the change of animal mood, such as IL-1ß 
and TNFα, showed a significant increase in cortex and striatum, a modulation of 
SERT activity in term of Km and Vmax was not detected, confirming again that no 
interaction between cytokines, p38 MAP kinase and SERT function in vitro nor 
in vivo was evident. In contrast, this study revealed a positive interaction 
between 5HT7 receptors and p38 MAP kinase in glia cells. However, this 
pathway was not present in cortical neurons where 5HT7 receptors did not 
activate p38 MAP kinase but instead increased the AMPAR subunit, GluR1 and 
CREB phosphorylation. The effect on GluR1 was reversed by the specific 5HT7 
antagonist, SB258719, and the PKA inhibitor, H89, confirming the specificity of 
response for 5HT7 receptors and the involvement of PKA in the mediation of 
GluR1 phosphorylation. In conclusion, this study displayed a lack of interaction 
between IL-1β and p38 MAP kinase on rat SERT while highlighting the effect of 
5HT7 receptors on p38 MAP kinase, with different functions between glial and 
neuronal cells. Noteworthy, this is the first report that showed a positive 
interaction between 5HT7 receptors and AMPA which stimulates new 
investigation into the role of 5HT7 receptors in neuronal plasticity.  
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Chapter 1      Introduction  
 
Section 1.1 Serotonergic system overview 
  
 
Serotonin (5HT) is a neuromodulatory neurotransmitter expressed in brain 
where it serves a wide array of physiological and behavioral functions. 5HT is 
also present, at a high concentration, in platelets from where it is released as a 
result of blood coagulation; this leading to its initial discovery (Zucker et al., 
1953). The first histological localization of 5HT was performed by 
histofluorescence techniques, which revealed the preferential localization of 
serotonergic neurons in cell body groups along the midline of the brainsteam 
(Dahlström and Fuxe, 1964). Nine groups of 5HT containing cell bodies were 
designated, B1-B9 (see diagram below). Development of immunohistochemical 
techniques made more accurate the detection of serotonergic neurons which 
were classified in two groups: the rostral group, confined to the mesencephalon 
and rostral pons, with major projections to the forebrain, and the caudal group, 
extending from the caudal pons to the caudal portion of the medulla oblongata, 
with major projections to the caudal brainstem and to the spinal cord. The 
rostral group includes the dorsal raphé nucleus (DRN) and median raphé 
nucleus (MRN) and together provides the majority of 5HTergic innervation to 
forebrain areas including the cerebral cortex, hippocampus, limbic system.  
5HTergic innervations were also observed in hypothalamus (Jacobs and 
Azmitia, 1992).  5HT is stored in vesicles and is released into the synaptic cleft 
following the stimulus.  5HT transmission is regulated through the 5HT 
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transporter (SERT, also known as SLC6A4), which transports 5HT from the 
extracellular to the  intracellular space, tryptophane hydroxylase which is the 
enzyme that regulates 5HT synthesis and monoamine oxidases (MOA, MOB) 
which regulate the degradation of 5HT and to its metabolites. Once 5HT is 
released, the synaptic signal is translated into the cell through specific receptors 
that are classified in seven families, 5HT1-7 receptors, comprising a total of 14 
structurally and pharmacologically distinct mammalian 5HT receptor subtypes.  
All these receptors regulate the complexity of serotonergic transmission and its 
involvement in a number of psychiatric conditions and behavioural traits.   
 
Schematic drawing depicting the localization of serotonergic cell body groups in a 
parasagittal section of the rat central nervous system and their major projections. OT, 
olfactory tubercolum; Sept, septum; C. Put, nucleus caudate –putamen; G. Pal, globus 
pallidus; T, Thalamus; H, habenula. Diagram obtained from Basic Neurochemistry: 
Molecular, Cellular and Medical Aspects. 6th edition. Siegel GJ, Agranoff BW, Albers 
RW, et al., editors. Philadelphia: Lippincott-Raven; 1999   
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Section 1.2 Effect of neuroinflammation on the serotonergic system 
 
Cytokines are messenger molecules with low molecular weight mainly involved 
in the regulation of the immune response. They are mostly produced by immune 
competent cells such as lymphocytes, macrophages, astrocytes and microglia 
and can be distinguished in two general groups: pro-inflammatory molecules 
that activate the immune response stimulating the defense system and anti-
inflammatory molecules which counteract the action of pro-inflammatory 
mediators thus dampening the immune response. The primary role of cytokines 
is therefore the regulation of the inflammatory response system. However, 
many clinical and preclinical studies have revealed that mediators of 
inflammation are also active in the CNS since an abnormal regulation of 
cytokine secretion may be associated with a negative effect on brain function 
which is a causative factor of behavioural, neuroendocrine and neurochemical 
features of major depressive disorder (MDD)(Raison et al, 2006; Schiepers et 
al.,2005; Capuron and Miller, 2011). Several clinical studies have suggested 
that depressive disorders are associated with an abnormal increase of pro-
inflammatory cytokines, while this level is often normalized with treatment 
response (Anisman et al.,2005; Dantzer et al., 2005; Lanquillon et al., 2000; 
Kulmatcycki and Jamali, 2006; Brien et al., 2006).  
Study to assess whether cytokines may be used as biological biomarkers for 
depression showed that mRNA expression of four pro-inflammatory cytokines 
IL-1β, IL-6, IFNγ, TNFα were significantly elevated in 20 depressed patients 
with respect to 22 healthy controls (table 1).  
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Table1. Cytokines in depressed patients and healthy controls (Tsao et al., 2006). 
 Total participants   
 Healthy control n=22 Patients (n=20) P values (t-test) 
IL-1β 0.14  1.18 0.74  0.95 0.0113 
IL-6 0.04   0.10 0.61   0.70 0.0017 
IFNγ 0.10  0.17 1.12  1.43 0.0047 
TNFα 0.02  0.04 0.58  0.70 0.0020 
All results were expressed as mean  S.D. and compared between controls and 
patients at baseline by Student t-test 
 
After a treatment with SSRI fluoxetine (20 mg daily for 3-month) which caused a 
reduction of 45% of the depression rate score in all subjects, only the IFNγ 
mRNA expression decreased significantly (Tsao et al., 2006). 
In a different study, quantitative measurement of IL-6, IL-8, TNFα, was 
performed in blood sample collected from 15 normal volunteers and 28 patients 
with major depression. As results, serum TNFα, IL-8 increased significantly in 
depressive patients compared to normal control whether IL-6 showed no 
significant difference between the two groups (Table 2).  
Table 2. Measurement of the inflammatory marker in normal controls and patients with 
depression (Mikova et al., 2001). 
 Total participants   
 Healthy control n=15 Patients (n=28) P values* 
IL-8 (pg/ml) 60  68 110  147 0.03 
IL-6 (pg/ml) 9.6   11.3 15.6   28.4 0.7 
TNFα (pg/ml) 14.7   8.0 33.4   27.4 0.005 
All results were expressed as mean  S.D. * Statistical analysis was performed using 
ANOVA, ANCOVA and Fisher’s least significant difference (LSD).  
 
Literature also revealed as the pro-inflammatory cytokine, IL-12, may have a 
role in the psychopathology. Recent clinical study involved 30 patients with 
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MDD showed a significant increase of IL-12 in plasma of depressive patients 
compared to normal control (Lee and Kim, 2006). Twenty cytokines were 
simultaneously assessed in 49 individuals with MDD and 49 healthy subjects. 
Multiple proinflammatory and two antinflammatory cytokines were significantly 
elevated in the MDD sample. The appearance of depressive symptoms seems 
to be more robustly associated with the increase of plasma concentrations of IL-
1β, IL-1α, IL-2, IL-6, IL-8, IFNy (Simon et al., 2007).   
The link between cytokines and depression was also supported by the use of 
cytokines in the treatment of some pathological conditions. IFNα, well known for 
its antiviral properties, is currently used in the treatment of diseases like 
hepatitis C, malignant melanoma and renal cell carcinoma. Administration of 
cytokines to non-depressed humans often induces a number of 
neuropsychiatric effects. Some of these effects can be directly associated with 
behavioural states of depressive patients such as cognitive impairment, 
decreased appetite, fatigue and loss of libido (Scheibel et al., 2004; Lieb et al., 
2006; Capuron et al., 2002). These symptoms almost immediately disappear 
after the termination of cytokine treatment, suggesting again an important role 
of cytokines in mediating these effects. 
When cytokines are administered to animals, a number of behaviours termed 
“sickness behaviour” are induced, mimicking some effects observed in humans 
after cytokine therapy and in MDD (Dunn et al., 2005; Yirmiya et al., 2006; 
Sudom et al., 2004). The most common features are hyperthermia, hypomotility, 
hypophagia, hyperalgesia, decreased interest in exploring the environment, 
decreased libido and increased time spent in sleeping.  Rats treated with a 
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lipopolysaccharide (LPS) bacterial cell wall component which stimulates a 
hyper-activation of the immune system, revealed a dose-related reduction of 
saccharin consuming, suggesting that the activation of immune functions 
induces anhedonia in rats.  LPS treatment induced other depressive-like 
symptoms, such as anorexia and reduced body weight, as well as reduction of 
social exploration (Yirmiya et al, 1996). The behavioural changes induced by 
LPS are indeed similar to those induced by a direct administration of cytokines 
(Sudom et al., 2004).  
More evidences of a link between the effect on animal behaviours and the 
depressive status induced by cytokines have been highlighted by the effect of 
common antidepressant compounds on animals treated with LPS or cytokines.  
LPS effects were reversed by an i.p. chronic administration of DAT and NET 
inhibitor, imipramine (Yirmiya R., 1996). The anhedonic effect (diminution in 
perceived reward or pleasure from otherwise rewarding stimuli or responses) 
induced by a single administration of LPS in rats was also prevented by a 
chronic treatment with selective inhibitor of noradrenalin transporters, 
Desipramine. In contrast, treatment with selective SERT inhibitor, paroxetine 
and serotonin/noradrenalin re-uptake inhibitor, Venlafaxine failed to alter LPS-
induced behaviours, underlining the complexity of the mechanisms that regulate 
antidepressant efficacy in attenuating LPS-induced behaviours. In the same 
study, desipramine reversed a rise of plasma TNFα secretion following LPS 
treatment, suggesting that desipramine protective effect may be due to its ability 
to inhibit the release of pro-inflammatory cytokines (Shen et al., 1999). The 
behavioural and physiological responses to a single administration of LPS in 
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rats have also been shown to be counteracted by chronic treatment with 
fluoxetine, which reversed the LPS-induced reduction of food consumption and 
body weight and also blocked the LPS-induced activation of the hypothalamic-
pituitary-adrenal (HPA) axis. (Yirmiya et al., 2001). Studies in rats have shown 
that a single i.p. administration of IL-1β decreased the consumption of “free” 
chow, which reflects anorexia, and also reduced responding for “earned 
sucrose rewards”, which reflects anhedonia. In the same investigation, 
fluoxetine abolished the effects of IL-1β on “earned” rewards, but was inactive in 
the reduction of chow intake, suggesting that this antidepressant drug was more 
active in preventing IL-1β-induced anhedonia (Merali et al., 2003). Further 
effects of antidepressant drugs in cytokine-induced sickness behaviours in 
animal models were reviewed in Dunn et al., 2005. 
Once cytokines enter the CNS, possible mechanisms that have been suggested 
to explain the alteration of neuronal functions is the modulation of monoamine 
concentrations especially 5HT with an effect that occurs in different brain 
regions and is dependent on the cytokines used. The focus of this PhD on the 
effect of cytokines on serotonergic neurotransmission is generated by the fact 
that this interaction has been largely supported by many in vitro and in vivo 
studies (see below). Moreover, some antidressant drugs such as fluoxetine and 
paroxetine which target SERT showed to reverse the depression symtoms and, 
in parallel, normalized the inflammatory response confirming the presence of an 
interaction between serotonergic system and cytokines (Kenis and Maes, 
2002). Moreover, some cytokines can direct modulate the expression and/or 
catalytic activity of SERT reflecting a change of 5HT level at the synapses as 
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described in the section 1.3.1.    In vivo microdialysis experiment in freely 
moving rats revealed that i.p. administration of IL-6 affected 5HT metabolism in 
the nucleus accumbens as shown by a significant rise of the principal 5HT 
metabolite, 5-Hydroxyindoleacetic acid (5-HIAA). Cytokine-treated rats showed 
also a decrease of dopamine (DA) concentration with a high concentration of 
the DA metabolite, dihydroxyphenylacetic acid (DOPAC) maintained over time 
(Song et al., 1999). Measurements of monoamine levels in mouse brain after 
repeated i.p IL-2 administrations showed a significant change on DA and 5HT 
metabolism with a reduction of DA and DOPAC in the caudate and substantia 
nigra, 5HT reduction in the medial prefrontal cortex and 5HT elevation in the 
hippocampus (La costa, 2000). In the nucleus accumbens, IL-1β did not affect 
DA concentrations but it significantly increased extracellular 5-HIAA 
accumulation, suggesting an increase of 5HT activity (Song et al., 1999). 
Peripheral IFNα chronic treatment caused changes in both DA and 5HT levels 
in many brain areas.  However, the most considerable effect was a depletion of 
5HT in frontal cortex, hippocampus, amygdala, thalamus, and hypothalamus, 
suggesting that these brain areas may be involved in IFN-α-induced rat 
sickness behavior (Sato et al., 2006). 
In an in vivo microdialysis study, i.p. LPS treatment displayed a significant dose-
dependent increase of extra-cellular 5HT levels and 5-HIAA in the rat 
hippocampus. This increase also correlated well with a decrease in active 
behavioural activity (locomotion, grooming, eating, drinking) and an increase in 
extracellular corticosterone levels. I.c.v. application of human IL-1β mimicked 
the effect of LPS on serotonergic neurotransmission, behavioural activity and 
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corticosterone levels. However, co-treatment with an IL-1 receptor antagonist 
reversed only the effect on extra-cellular 5HT concentration, suggesting that IL-
1β may mediate LPS effect on hippocampal serotonergic transmission 
(Linthorst et al., 1995). All these studies therefore support a role for cytokines in 
the regulation of monoaminergic neurotransmission into the CNS, in particular 
in the change of serotonergic concentrations in brain. 
    
Section 1.3 5HT transporter expression and structure  
 
One of the most important targets involved in regulating levels of 5HT in the 
brain, is the 5HT transporter (SERT, also known as SLC6A4), which transports 
5HT from the extracellular space and then regulates 5HT levels in the 
synapses.  In the mature animal, it is located perisynaptically on presynaptic 
5HT nerve terminals as well as on axons and 5HT cell bodies in the Raphe 
nucleus (Rudnick and Clark, 1993; Barker & Blakely, 1996; Blakely et al., 1998). 
The localization of 5HT transporter immunoreactivity in terminal endings and its 
concentration within varicosities are in good agreement with the high levels of 
5HT and 5HT uptake found at these sites. SERT is predominantly expressed in 
caudate-putamen, cerebral cortex, amygdaloid complex, substantia nigra and 
Raphe nuclei, and low levels in the cochlear and vestibular nuclei and the 
cerebellum (Sur et al., 1997). Antisense oligonucleotide probes derived from the 
cloned human placental SERT cDNA (Ramamoorthy et al. 1993) reveal dense 
SERT hybridization signals overlying neurons, but not glia, of the dorsal and 
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median raphe nuclei and the serotonergic caudal linear nucleus in post-mortem 
human brain sections (Austin et al.1994).  
SERTs are also expressed on non-neuronal cells including platelets, 
lymphoblasts, monocytes, enterochromaffin cells, endothelial cells and 
placental syncitiotrophoblasts (Daws and Gould, 2011). Human SERT (hSERT) 
is localized in the chromosome 17q11.2 (Ramamoorthy et al., 1993) and 
encodes a protein of 630 amino acids.  The structure predicted for brain SERT 
is similar to the other monoamine transporters such as noradrenalin transporter 
(NET), and dopamine transporter (DAT) and belongs to the single gene SLC6 
family. The molecular structure is a dimer of 60-70 KDa characterized by 12 
hydrophobic transmembrane domains with cytoplasmic NH2 and COOH termini 
bearing greatest sequence identity to other gene family members in TMDs 1–2 
and 5–8. It has been suggested that these conserved regions are involved in 
general transport functions while less conserved regions such as the COOH 
and NH2 terminal are mainly involved in the pharmacological selectivity. Other 
studies where some regions of SERT were exchanged with NET did not show a 
loss of substrate or antagonism specificity suggesting that COOH and NH2 were 
not important in target recognition (Zahniser et al., 2001). Transmembranes 3 
and 4 are separated by a large, hydrophilic loop that bears two canonical sites 
for N-linked glycosylation (Ramamoorthy et al., 1993). SERT exists also in 
homo-multimeric complexes and contains potential phosphorylation sites for 
PKC, PKA and p38 MAP kinases as indicated in the diagram below 
(Ramamoorthy et al., 2010).   
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Pre-synaptic receptors and intracellular signal pathways are linked with kinases 
regulating the activity of SERT in term of expression, functionality and transport 
in the plasma membranes. For example, activation of adenosine receptors 
(AR), 5HT1B, histamine receptors (H3R) and BDNF/TrkB stimulates 5HT uptake 
(Launay et al., 1994; Zhu et al., 2004; Benmansour et al., 2008), whereas α2 
adrenergic receptor stimulation reduces 5HT uptake (Ansah et al., 2003). The 
mechanism of the different efficiency of amine transport following SERT 
Putative structures of the rat 5HT transporter (SERT) showing homologous amino acids 
with the rat dopamine transporter (DAT), human norepinephrine (NET) or both. Possible 
phosphorylation (P) sites are shown, as are possible glycosylation sites on the large 
second extracellular loop. 
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phosphorylation is explained by a change of SERT recycling in the plasma 
membranes and its surface expression (Ramamoorthy et al., 2010).   
Moreover, different human SERT variants associated with the risk of developing 
brain diseases showed an altered sensitivity to be activated by cGMP-
dependent protein kinase (PKG) and p38 MAP kinase suggesting that an 
altered regulation of SERT by kinases may be associated with the risk of 
developing depression (Prasad et al.,2005). However, the degree to which 
kinases regulate SERT surface expression is controversial due to many 
discrepancies across different laboratories and unclear evidence supportive 
trafficking but also non-trafficking dependent mechanisms (Miller & Hoffman, 
1994; Kilic et al., 2003). 
5HT transport operates by using the gradient of Na+ and Cl- ions as the driving 
force to accumulate 5HT inside the cells against gradient.  Basically, the influx 
of 5HT is coupled with the influx of Na+ and Cl- ions and the efflux of K+ ion in 
each cycle. The rapid reuptake of 5HT in the synapses plays an important role 
in determining duration and intensity of 5HT transmission with post-synaptic 
receptors placed in limbic region mediating emotion and pre-synaptic receptors 
that exert inhibiting control of 5HT neurons. The interest for this 
neurotransmitter transporter is highlighted by the number of drugs targeting this 
protein that have relevant benefits in the treatment of psychiatry disorders such 
as depression and anxiety. For example, tricyclic antidepressants, a large class 
of anti-depressive compounds, are actually 5HT reuptake inhibitors (SSRI). In 
an attempt to understand the molecular mechanism of the positive effect of 
SSRI in depression, many publications highlighted that SSRIs increase the level 
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of 5HT by directing inhibition of transporter but also can alter SERT expression 
(White et al., 2005). Changes to the expression level of SERT in response to 
drugs could contribute to neuroadaptive changes associated with chronic 
antidepressant administration. However, the effects of antidepressants on the 
regulation of SERT expression remain largely unclear. It has been identified that 
a polymorphism in the promoter region of the human SERT gene resulted in a 
deletion of a 44-basepair repeat. Activity of the form with longer sequence (l) 
was three fold increased compared to the short form (s). Moreover PKC- and 
cAMP-activated transcription was significantly greater at the “l” SERT gene 
promoter versus the “s” promoter. This change reflects a different response to 
antidressant activity and response; for example patients with an “l” allele (either 
as “l / l” or “l / s”) exhibited an increase in the response to fluoxetine and 
placebo compared to subject with the “s” genotype (Lesch et al., 1996).  
   
Section 1.3.1 Effect of cytokines and their signal pathways on SERT  
 
A mechanism proposed that may describe how cytokines alter 5HT levels in 
brain is by the modulation of 5HT transporter expression and then a change of 
re-uptake of 5HT at the synaptic cleft. Exposure of JAR human chotiocarcinoma 
cells to IL-1β for at least 16 hours at 37°C increased 5HT uptake two fold and 
this effect was mainly due to an increase of maximal velocity of uptake rate 
while effect on affinity was minimal. Further RTI-55 binding experiments 
confirmed an increase of density of SERT in the plasma membranes following 
treatment and Northern blot studies also showed an increase of 5HT transporter 
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mRNA in treated cells compared to control confirming an activation of SERT 
expression induced by IL-1β (Ramamoorty et al., 1995). The effect of other 
cytokines were revealed by additional kinetic analysis of SERT on JAR human 
chotiocarcinoma cells treated with 50ng/ml TNFα for at least 48 hours at 37°C 
which revealed a significant increase of the maximal velocity of uptake 
compared to non-treated cells whereas an effect on Km was absent suggesting 
a change of only SERT expression. The same publication reported no effect 
when cells were treated with increasing concentrations of IL-6 (0.1-100ng/ml; 
Mossner et al., 1998).  In contrast to previous reports, TNFα and INF  
decreased 5HT uptake when incubated for 72 hours with immortalized human 
intestinal epithelial cell line (Caco2 cells) due to a decrease in SERT expression 
(Foley et al., 2007). Treatment with INFα or  for 3–6 h, but not for 30 min, 
increased the uptake activity of the 5HT transporter in human placental 
choriocarcinoma cells (BeWo cells) and this effect was accompanied by an 
increase of SERT mRNA. The same treatment increased the level of SERT 
mRNA in the midbrain and adrenal gland from mice suggesting that SERT 
espression is modulated also in vivo. Uptake rate in IFN-treated mice was not 
measured. The finding that treatment with interferons for a short time (30 min) 
did not alter 5HT uptake suggests that the uptake function of the 5HT 
transporter is not enhanced by short-term interferon-mediated signalling which 
involved a direct tyrosine phosphorylation of the 5HT transporter (Morikawa et 
al., 1998).  A different response in rat is suggested by an in situ hybridization 
study where a chronic i.p. administration of INFα (20000 up to 2000000 IU/kg 
for 14 days) did not produce any significant change in the 5HT transporter 
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mRNA levels in rat dorsal raphe nucleus (Sato T et al, 2006). The discrepancy 
observed in these findings may be due to a different effect of a chronic vs acute 
treatment with cytokines. Analysis of the effect of acute vs chronic IL-1β 
administration showed that despite the acute effect of cytokines being 
attenuated, the chronic IL-1β administrations showed an increase alteration of 
5HT and NE utilization with an elevation of 5HT2C, 5HT1B receptor expression 
(Anisman et al., 2008).  Moreover, the levels of monoamines and associated 
metabolites after chronic and acute i.p. IFNα administration were measured in 
various regions of the rat brain using a high-performance liquid 
chromatography–electrochemical detection system. A depletion of 5HT in the 
frontal cortex, hippocampus, amygdala, thalamus and hypothalamus was 
observed in rats given a moderate-dose of IFNα for 14 days while acute IFNα 
did not change 5HT level (Sato et al., 2006). The importance of chronic 
exposure of cytokines on depression was confirmed by some particular 
situations characterized by a chronic low-grade inflammatory such as chronic 
stress, obesity and aging which appear as  vulnerability factors for development 
neuropsychiatric diseases (Capuron et al., 2011).   
The effect on SERT was not only due to the alteration of expression but also by 
a change of biophysical characteristics at the synapses. A paper revealed that 
IL-1β and tumor necrosis factor alpha (TNF-α) stimulated 5HT uptake in both 
the rat embryonic raphe cell line, RN46A, and in mouse synaptosomes. In 
RN46A cells, both cytokines stimulated 5HT uptake in a concentration- and 
time-dependent manner with a maximum effect at 100 ng/ml and after an 
incubation of 20 min with cells. Similarly, an increase of 5HT uptake was also 
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produced in mouse midbrain and striatal synaptosomes although the maximum 
effect occurred at lower concentrations (10 and 20 ng/ml for IL-1  and TNF-α 
respectively) and over a shorter incubation time (10 min). Interestingly, 
experiments on RN46A cell demonstrated that IL-1β and TNF-α treatments 
decreased Km  (uptake parameter which reflects the affinity of 5HT for 
transporter) whereas the Bmax (uptake parameter which reflects expression of 
SERT in the membrane) was not changed by IL-1β and just partially affected by 
TNFα. Finally, in both RN46A cells and synaptosomes, the effects of these 
cytokines were completely (IL-1β) or partially (TNF-α) blocked by a selective 
p38 MAPK inhibitor, SB203580 suggesting that the regulation of neuronal SERT 
activity induced by cytokines may be mediated by p38 MAPK-linked pathways 
(Zhu et al., 2006). Interestingly, the role of p38 MAP kinase in the modulation of 
SERT had been already demonstrated in recombinant cells expressing human 
SERT and in RN46A cells. Measurement of 5HT uptake in these cells treated 
with the indirect unselective p38 MAP kinase activator, anisomycin (1µM), 
revealed an increased uptake rate due to a reduction in the Km. This study also 
revealed that anisomycin increased the 5HT uptake rate in human platelets 
(Zhu et al, 2005).  
Literature has also reported that in CHO cells stably expressing human SERT, 
NET and DAT, activation of p38 MAP kinase increased 5HT and noradrenalin 
(NA) uptake but decreased DA uptake. This suggests that p38 MAP kinase 
mediates a catalytic activation or deactivation of all human monoamine 
transporters.  
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Taking together, these findings suggest that the regulation of neurotransmission 
by cytokines may depend on a direct change of the transporters functionality 
causing a different efficiency in the reuptake of monoamines, especially 5HT.  
 
Section 1.4 5HT7 receptor structure and function  
 
5HT7 receptors represent the most recently identified target within the big class 
of 5HT receptors (Barnes and Sharp et al., 1999). Structural studies showed 
that this receptor is a protein of about 445 amino acids and with the 
characteristic seven putative membrane spanning regions with a high degree of 
homology with other species. The human 5HT7 receptor gene is located on 
chromosome 10 (10q21-q24) (Gelernter et al., 1995), and contains several 
introns (Gellynck et al., 2008). The second intron corresponds to the carboxyl 
terminus of the 5HT7 receptor, from which at least four splice variants were 
reported.  Human and rat tissue appear to express only three isoforms. In 
particular, rats express 5HT7A, 5HT7B, 5HT7C because the exon responsible for 
the fourth isoform 5HT7D is absent.  Humans express 5HT7A, 5HT7B, 5HT7D 
which are proteins of 445, 432 and 479 amino acids respectively (Gellynck et 
al., 2008). Investigation of the distribution of the different splice variants led to 
the observation that all variants were present in most tissues examined, 
although relative expression levels differ considerably. In man and rat, the 
5HT7A and 5HT7B splice variants are the most abundant splice variants, whilst 
the rat 5HT7C and human 5HT7D splice variants represent 4% of the total brain 
5HT7 mRNA (Vanhoenacker et al., 2000; Guthrie et al., 2005). 
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Many studies used in situ hybridization to determine where the 5HT7 receptor 
mRNA was expressed within the brain. These studies detected a high 
expression of 5HT7 receptor mRNA in mice and rats within regions of the 
thalamus, hypothalamus and hippocampus with generally lower levels in areas 
such as the cerebral cortex and amygdala (Neumaier et al., 2001). 
Immunocytochemistry analysis of 5HT7 receptor protein confirmed the 
distribution obtained with in situ hybridization, highlighting its expression in cell 
bodies and fibres of all CA fields (CA1, CA2, CA3) in the hippocampus and in 
the suprachiasmatic nucleus (SCN) of the hypothalamus (Muneoka et al., 
2003). The distribution of 5HT7 receptors was also analyzed using the selective 
5HT7 receptor antagonist radioligand [3H]SB-269970 in various rodent (mouse, 
rat)  and non-rodent (pig, marmoset) species (Thomas et. al., 2002) and human 
brain whole hemisphere autoradiography (Varnas K et. al., 2004). The results 
confirmed that 5HT7 receptors are most abundantly localized in the anterior 
thalamus and in the dentate gyrus. Other regions containing intermediate levels 
of 5HT7 receptors included the hypothalamus, anterior cingulate gyrus, 
hippocampus, amygdala and certain brainstem nuclei. A similar binding pattern, 
but with some notable difference, was found in rats, guinea-pigs and humans 
using [3H]mesulergine as the radioligand (Hemedah et al., 1999). These data 
highlighted a relatively high binding density in the caudate-putamen in rats, 
guinea-pigs and human, although other studies did not report binding in this 
regions. In other regions, these findings confirmed the immunohistochemistry 
data.  
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Since the 5HT7 receptor is positively coupled with Gs protein, its activation 
stimulates an increase of intracellular adenylate cyclase (AC). This effect 
generally leads to important changes of cellular activity through an activation of 
various intracellular kinases (PKA and PKC) that trigger a series of down-
stream signalling cascades and a consequent modulation of gene expression. 
Increase of cAMP induced by 5HT7 receptors was reported in various 
recombinant cell systems transfected with human and rat 5HT7 receptors (Mahe 
et al., 2004; Romero et al., 2006). Moreover, accumulation of cAMP induced by 
5HT7 receptors was also discovered in many glioblastoma cell lines (Mahe et 
al., 2004), rat cultured astrocytes (Hirst et al., 1997) and guinea-pig 
hippocampal membranes (Thomas et al., 1999). Physiological functions of 5HT7 
receptors in the central nervous system are various and depend on the area in 
which they are expressed. Overall, the expression of these receptors in the 
hypothalamus could be associated with the modulation of circadian rhythm, 
thermoregulation and endocrine regulation. The presence in thalamus, cortex 
and hippocampus might be important for sleep and mood regulation, and it has 
been suggested that thalamic 5HT7 receptors might be important in epilepsy. 
Finally, 5HT7 receptors in the hippocampus are of interest in synaptic plasticity 
which is important for learning and memory.   
The role of 5HT in thermoregulation was well reported when Li et al (2001) 
showed that 8-OH-DPAT (non selective 5HT1A and 5HT7 agonists) reduced 
body temperature in mice and this effect was preliminarily associated just to 
5HT1A receptors. The involvement of to 5HT7 receptors in the control of body 
temperature was assessed when further studies showed that selective 5HT7 
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receptor antagonists reversed the hypothermia induced by 5CT and 8-OH-
DPAT (Hedlund et al.,2004). Recently, this finding was confirmed in mutant 
5HT7 receptors knockout mice which were injected i.p. with the 5HT7 receptor 
agonist LP-211. This compounds seemed to dose-dependently reduce body 
temperature in 5HT7+/+ mice but not in 5HT7−/− mice confirming the capacity of 
5HT7 receptor agonist to regulate body temperature in vivo. 
Other investigations were focused to understand the role of 5HT7 receptors in 
the control of circadian rhythm.  A first evidence of this modulation was provided 
in rat hippocampal slices where 8-OH-DPAT induced a phase shifts of the 
circadian rhythm of spontaneous neuronal activity within the SCN (Lovenberg et 
al., 1993). Further studies highlighted that this effect was reversed by 
unselective 5HT7 receptor antagonist, SB-269979 supporting the involvement of 
5HT7 receptors (Sprouse et al., 2004). However, in one study, the selective 
5HT7 receptor agonist AS19 administered in rats at one concentration failed to 
produce the effect observed with 8-OH-DPAT but the partial agonism of AS19 
could make difficult the comparison (Cuesta et al., 2009).  Moreover, studies 
availing of 5HT7 receptor knock-out mice and selective antagonists showed that 
5HT7 is also involved in the photic regulation of retinohypothalamic input to the 
SCN (Gardani  and Biello ,  2008).  
Studies highlighted expression of 5HT7 receptors in the hippocampus 
suggesting that 5HT7 receptors may play an important part in neuronal 
plasticity. Further studies were then performed to understand the physiological 
function of 5HT7 receptors in the control of neuronal firing and Long term 
potentiation (LTP) in hippocampus. Intracellular recording in area CA3 of 
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hippocampal slice showed that 5HT7 receptors reduced the amplitude of slow 
afterhyperpolarization (sAHP) in pyramidal neurons in a reversible, 
concentration-dependent manner. Mechanistically, this effect appeared to occur 
through an inhibition of Ca2+ activated K+ channels (Bacon WL et al., 2000). The 
reduction of sAHP induced by 5HT7 receptors was the mechanism that 
explained the increase of bursting frequency induced by 5CT in the same region 
(Gill at al., 2002).  Moreover, the same study revealed that 5CT did not affect 
AMPA receptor mediated synaptic transmission as assessed by the effect of 
this 5HT7 receptor agonist on stimulus evoked field and intracellular recorded 
Excitatory PostSynaptic Potential (EPSPs).            
In CA3 pyramidal slices the effect was similar to that reported in the CA1 region 
where 5CT activates 5HT7 receptors to increase neuronal excitability (Tokarski 
el al., 2003). A role of 5HT7 receptors in neuronal plasticity was confirmed in 
mutant 5HT7 knock-out mice which showed a reduced ability to induce long-
term potentiation (LTP) within the CA1 region of hippocampal slices (Roberts 
et.al., 2004). In hippocampal cultured neurons, 5HT7 receptors activated the 
mitogen-activated kinases ERK1 and ERK2 which may be relevant for the effect 
on LTP (Errico et al., 2001). 
The effect of 5HT7 receptor antagonists on neuronal physiology increased the 
interest to understand the role of 5HT7 receptors in brain. In particular, the 
interaction between antidepressants with 5HT7 receptors has forwarded a link 
with the control of mood. Several antidepressants induced  c-fos expression in 
SCN and this effect was consistent with the expression of c-fos after the 
activation of 5HT7 receptors (Mullins et. al., 1999). Moreover  chronic 
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antidepressant drug treatment led to a reduction of 5HT7 receptors binding sites 
in the brain (Mullins et. al., 1999). Activity in the forced swim test and the tail 
suspension test suggested a potential link between 5HT7 receptors and mood. 
Pharmacological blockade of the 5HT7 receptor or inactivation of the receptor 
gene led to an antidepressant-like behavioural profile, that is, reduced 
immobility (Hedlund et al. 2005; Guscott et al. 2005; Bonaventure et al. 2007; 
Wesolowska et al. 2006a, b, 2007). A synergistic interaction was also apparent 
between the 5HT7 receptor antagonist SB-269970 and antidepressants leading 
to reduced immobility in both the forced swim test and the tail suspension test 
(Bonaventure et al. 2007; Wesolowska et al. 2007). Thus, concurrent 
administration of citalopram, an antidepressant of the SSRI type, and SB-
269970 has been shown to reduce immobility in the tail suspension test in 
C57BL/6 J mice (Bonaventure et al. 2007). This synergistic effect was also 
detected in the rat frontal cortex measuring the 5HT concentration after the 
exposure to citalopram and SB-269970. At a higher dose, SB-269970 alone 
reduced immobility in the mouse tail suspension test without any change of 5HT 
concentration in the rat frontal cortex (Hedlund et al. 2005; Bonaventure et al. 
2007), However, the combination of a low dose of SB-269970 and a low dose of 
citalopram increased the level of 5HT in the frontal cortex (Bonaventure et al. 
2007). A similar synergistic interaction between SB-269970 and citalopram has 
also been demonstrated in the forced swim test (Wesolowska et al. 2007). 
Other classes of antidepressants used in this study gave a similar positive 
interaction. Thus, when sub-threshold doses of imipramine, desipramine, and 
moclobemide were injected in the mouse in combination with SB-269970, 
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animals revealed reduced immobility in the forced swim test (Wesolowska et al. 
2007). The interaction between SB-269970 and imipramine has also been 
shown in the forced swim test using Wistar rats in which the effect on immobility 
was accompanied with an increase in 5HT levels in the prefrontal cortex 
(Wesolowska and Kowalska 2008).  
Another model to study mood disorders is the exposure to chronic unpredictable 
mild stress that generate a depression-like state in laboratory animals (Willner 
et al. 1992). In a recent study, rats exposed to such stress showed 5HT7 
receptor mRNA upregulation in the hippocampus and hypothalamus, but not 
cortex (Li et al. 2009). The change in mRNA levels could be inhibited by 
treatment with fluoxetine and curcumin, an active ingredient in turmeric extracts 
(Li et al. 2009).  Interestingly, a clinical study has shown that the 5HT7 receptor 
is relevant for the treatment of depression. Amisulpride is an atypical 
antipsychotic that is also a proven antidepressant (Smeraldi 1998). The 
antidepressant effect of amisulpride was firstly associated to somehow rely on 
its properties as a dopamine D2/D3 receptor antagonist, although the 
mechanism has never been satisfactorily explained. It has now been 
demonstrated that amisulpride has high affinity for 5HT7 receptors and that 
amisulpride reduces immobility in both the tail suspension test and the forced 
swim test in 5HT7 +/+ mice but not in 5HT7−/− mice (Abbas et al. 2009). These 
findings provide at least indirect evidence that the antidepressant effect of 
amisulpride is mediated by the 5HT7 receptor. It should also be noted that 
aripiprazole, another atypical antipsychotic that is successfully used to augment 
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the effect of traditional antidepressants (Berman et al. 2009), has high affinity 
for the 5HT7 receptor (Shapiro et al. 2003).  
 
Section 1.4.1 5HT7 receptors and neuroinflammation 
 
Microglial cells and astrocytes represent the cellular sources of cytokines in the 
CNS. Microglia cells secrete Th1 cytokines (T helper type 1 cells) while 
astrocytes preferentially release Th2 cytokines (T helper type 2 cells). Since 
some psychiatric diseases seems to be associated with an Th1/Th2 imbalance 
with a shift to Th1, the equilibrium between microglial and astrocytes cytokine 
release may be an important feature in abnormal regulation of 
neuroinflammation leading to depression (Muller & Schwarz, 2007).  
5HT7 receptor expression functionally coupled with cAMP accumulation was 
confirmed in rat brain astrocytes (Hirst et al., 1997), in human microglia cells 
(Mahe et al., 2005) and in human glioblastoma cell lines (U-373 MG, DBTRG-
05MG, T98G, H4, U-138 MG, U-87 MG, CCF-STTG1, Hs 683) (Mahe et al., 
2004). Moreover, 5HT has been shown to stimulate the expression and release 
of IL-6 in a human glioblastoma cell line U-373 MG and microglial MC-3 cell line 
(Lieb et al., 2005; Mahe et al., 2005). In human glioblastoma cell line U-373 
MG, IL-6 release induced by 5HT was mediated by 5HT7 receptors. The time 
course experiment revealed two peaks, one after 4 hours and the second after 
48 hours with a high level of IL-6 till 72 hours from stimulus. This data may 
suggest two transduction pathways are involved, one rapid and transient and 
other delayed but persistent. This effect was blocked in the presence of the 
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selective 5HT7 receptor antagonist, SB269970, while selective 5HT2A and 5HT3 
receptor antagonists were unable to reverse the 5HT induced IL-6 release. IL-6 
release induced by 5HT was also blocked by p38 MAP kinase and PKC 
inhibitors (SB202190 and GF109203X, respectively) while p42/44 MAPK 
inhibitor PD98059 did not change the response suggesting that this effect is 
mainly mediated by p38 MAP kinase and PKC. Western blot analysis of cells 
lysates treated with 5HT showed that activation of p38 MAP kinase started at 5 
min with a peak at 10 and 15 min and disappeared after 60 min, while activation 
of PKC stared at 2.5 min lasting untill 10min. In the attempt to further explore 
which PKC isoforms that were involved, a variety of PKC inhibitors were used. 
These data indicated that atypical PKCs (PKC  and ) were involved but not 
classical PKC (PKCα,β, ). No consistent evidence for the involvement of 
transcription nuclear factor kappa B was reported. Within the human microglial 
MC-3 cell line, stimulation with the non-selective agonist of 5HT7 receptors, 
5CT, caused an increase in IL-6 mRNA which was also abolished by the 
presence of the 5HT7 receptor antagonist SB269970 (Mahe et al., 2005). 
Considering that in this cell line, 5HT7 receptors increase cAMP increase and 
forskolin mimicked the effect of 5CT or 5HT on IL-6 expression, it has been 
suggested that  cAMP intracellular signal pathway is involved.  
Overall, these evidences suggest that 5HT7 receptors may play an important 
role in the regulation of cytokine release in the CNS. However, since four splice 
variants of 5HT7 have been identified, it is not yet known how different splice 
variants of the 5HT7 receptor may differentially modulate cytokine release.   
26 
 
Section 1.5 Alternative mechanisms of action of cytokine-induce 
depression.  
 
As described in the previous section, clinical and preclinical studies suggested 
that the abnormal regulation of cytokines in the CNS may cause a change of 
neurotransmission which is strongly associated with the development of 
depression. Apart from the effect of cytokines on serotonergic system described 
above, alternative mechanisms seem relevant in the correlation between 
immune response with depression.  
The main resource of cytokines in the brain are microglia and astrocyte which  
produce brain cytokines belonging to the Th1 (such as IFN , IL-1, TNF )  and 
Th2 (such as IL-4 and IL-10) class respectively. An inappropriate balance of 
microglia and astrocyte as found in some patients with depression (Johnston-
Wilson et al., 2000; Miguel-Hidalgo et al., 2000; Rajkowska et al., 2007) could 
determine an abnormal regulation of these cytokines. Moreover, microglia and 
astroglia play a role through the secretion of neurotoxic substance and 
neurotrophic factors which influence the neuronal plasticity and neuronal toxicity 
confirming the importance of appropriate numbers of microglia/astrocyte in the 
CNS (Leah McNally et al., 2008)   
In microglia, there is an induction of neuronal cytotoxicity via the cytokines-
dependent stimulation of enzyme indoleamine 2,3-dioxygenease (IDO). IDO 
that converts the main precursor of serotonin, tryptophan (TRP), into kynurenine 
(KYN), has been demonstrated to be activated by cytokines, reducing TRP 
availability and consequently decreasing 5-HT concentrations in the brain. In 
parallel, a cytokine-induced augmentation of KYN produces an increase of the 
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NMDA receptor agonist quinolinic acid in the brain (Dantzer et al., 2010). A 
depletion of TRP along with an increase of quinolinic acid and consequently an 
altered glutamatergic neurotransmission are strongly associated with 
depression (Muller & Schwarz MJ, 2007).  
Hyperactivity of the HPA axis induced by cytokines including increased 
production and release of CRH in response to stress, has been proposed as an 
alternative mechanism that associates inflammation with the developing of 
neuropsychiatric disorders (Raison et al., 2006). This hypothesis was confirmed 
in patients who developed depressive behaviours after INFα therapy and an 
exaggerated increase in adrenocorticotropic hormone and cortisol levels in 
response to INFα treatment (Capuron et al., 2003) 
 This hyperactivity of the HPA axis response may derive from the capacity of 
cytokines to alter GR expression and/or GR function (Pace et al., 2007, Miller et 
al., 1999 & 2001, Wang et al., 2004) which are very important to dampen the 
neuroendocrine and inflammatory responses induced by stress and pathogen 
exposure.  
Another hypothesis, which links inflammation to neuroplasticity, is the regulation 
of the nerve growth factors like BDNF by cytokines. BDNF plays an important 
role in the control of neuronal differentiation, neuroplasticity and 
neuroprotection, therefore a loss of BDNF is increasingly being implicated in the 
pathophysiology of depression (Groves, 2007; Martinowich and Lu, 2007; 
Palomino et al., 2006). A production of BDNF was detected in 
immunecompetent cell lines and in inflammatory brain lesions, highlighting the 
possibility of a neuronal protective role of the immune system (Hohlfeld et al., 
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2007). In the CNS, human cultured adult astrocytes stimulated with TNFα and 
IL-1ß showed two-fold increased mRNA expression of BDNF (Meeuwsen et al., 
2003). Moreover, intra-hippocampal admistration of IL-1β and IL-1β receptor 
antagonist antibody (Amgen) into rat brain modulate the level of BDNF mRNA 
expression following learning and memory tasks and social isolation (Barrientos 
et al., 2003). Peripheral inflammation induced by LPS injection led to a 20% 
transient decrease of BDNF protein expression in mouse brain synaptosomes 
(Schnydring et al., 2007). In conclusion, these findings suggest that cytokines 
may regulate the level of BDNF within the CNS level that can ultimately alter 
synaptic plasticity and hence brain function though this hypothesis is young in 
its evolution (Raison et al., 2006). 
 
Section 1.6 Aims 
 
Overall, these studies suggest a correlation between immune activation and 
psychiatry symptoms but the number of mechanisms described indicates that 
the nature of interaction among cytokines, the brain function and the change of 
behavior is still not well identified. Understanding the mechanism that better 
described this interaction may help to create new prospects for developing new 
drugs with increased efficacy for the treatment of psychiatric diseases.          
The mechanism stated in this thesis is a modulation of the 5HT transport as 
consequence of a direct modulation of SERT function induced by TNFα and IL-
1β at the synapses level. This effect may have an important impact on 5HT 
post-synaptic signalling which links with cytokines release because the 5HT7 
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receptors expressed in glial cells potentiate the release of cytokines in the brain. 
It means that serotonin has a dual interaction with the cytokine pathway: on one 
hand increasing the 5HT transport, cytokines may induce critical changes of 
serotonin level at the synapses that may link to the development of depressive-
like behaviors. On the other hand, serotonin may have a role in the release of 
cytokines in the brain and then an imbalance of Th1:Th2 types with 
consequently dysregulation of neuronal physiology. 
All these processes involve a signalling cascade that have a common mediator, 
p38 MAP kinase, which is activated by numerous cytokines as well as by 
environmental and chemical stressors in many cases triggering inflammatory 
and apoptotic pathways (see figure below).  .    
This work was then focused on understanding the regulation of SERT induced 
by cytokines; in particular, studying if activation of p38 MAP kinase induced by 
IL-1β or anisomycin induced a significant change of rat SERT function and 
expression. The use of IL-1β and anisomycin was justified by the literature 
showing that IL-1β and anisomycin treatment induce a direct activation of SERT 
(Zhu et al., 2006) and the sickness behavior after LPS challenge is mainly 
mediated by IL-1β receptors via p38 MAP kinase (Zhu et al., 2010, Dunn et al., 
2005). In order to correlate the proposed in vitro mechanism and the effect 
observed in animal model, this in vitro approach was followed by ex vivo studies 
in which SERT function was also measured in rats treated with LPS, a potent 
stimulator of inflammation. Moreover, additional studies were performed to 
characterize the expression and function of 5HT7 receptors in primary cultured 
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astrocytes and neurons and then explore the signalling cascade at downstream 
of 5HT7 receptor activation with regards the interaction with p38 MAP kinase.    
The impact of this proposed study will be a clarification of the relationship 
between the serotonergic signal and cytokines pathway, in particular the 
interaction among cytokines, p38 MAP kinase, SERT and 5HT7 receptors in the 
context of immune response and psychiatry disorders. Understanding the 
mechanism of this interaction and which targets are more involved, will give the 
possibility to develop new antidepressant therapies based on the modulation of 
these pathways.  
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Chapter 2      Materials and Methods  
 
Section 2.1 Measurement of 5HT uptake in rat and mouse brain 
synaptosomes  
  
The assay currently adopted to measure the SERT function is an [3H]5HT 
uptake assay. This assay can be performed in both recombinant cells and in 
native tissue and give the measurement of 5HT uptake rate mediated by SERT. 
The native tissue has to be processed to obtain brain synaptosomes which are 
vesicles generated by the synaptic termination containing the targets present in 
the synaptic cleft. [3H]5HT uptake was measured in brain synaptosomes 
prepared from Sprague Dawley rats (Charles river, 225-250g) housed in groups 
of 4 animals per cage and from C57BL/6N mice (Harlan, 12 weeks) housed in 
groups of 5 animals or in single animals per cage. The assay was performed 
using two different protocols. “Protocol 1” was based on those reported by 
Thomas et al., (1987). “Protocol 2” was based on those reported by Zhu et al., 
(2007).  
Protocol 1  
Brain tissue from single animal was dissected from different animalson ice and 
put into a tube containing 10ml cold 0.32M sucrose. The content of the tube 
was homogenised using 8 strokes of a Potters-Manheim homogeniser set at 50 
rpm. The homogenate was centrifuged for 5 min at 1000xg at 4°C. Supernatant 
containing synaptosomes was collected, transferred into a new tube and diluted 
1:2 (V/V) in 0.32M sucrose. 10 l of synaptosomes were stored at -20°C and 
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use for protein determination. 100 l of synaptosomes (30-40 g/well) were pre-
warmed in a bath at the assay temperature of 30°C for 10 min. 350 l assay 
buffer (118mM NaCl, 4.9mM KCl, 1.5mM CaCl2*2H2O, 1.2mM MgSO4*7H2O, 
25mM NaHCO3, 1.2mM NaH2PO4, 0.06mM L-ascorbate, 10mM glucose, 
0.01mM pargyline) with vehicle (0.1% DMSO in assay buffer) or compounds 
were then added to 100 l synaptosomes for 5-30 min. 5HT uptake was initiated 
by adding 50µl of [3H]5HT (10-20 nM final concentration) and after 10 min the 
reaction was stopped and synaptosomes separated by rapid filtration through 
GF/B Whatman paper using Brandel harvester. Filter was washed there times 
with ice-cold assay buffer. After immersing filters in scintillation liquid for 6 
hours, radioactivity was evaluated by scintillation counting. Counts were 
normalized per min and per mg of protein detected in the frozen samples.  
Protocol 2 
 The brain tissue from single animal was dissected out on ice as above and 
homogenized in 10 volumes of cold 0.32M sucrose using 8 strokes of a Potters-
Manheim homogeniser set at 400 rpm. The homogenate was centrifuged for 10 
min at 800xg at 4°C. The supernatant was transferred into a new tube and 
centrifuged at 10000xg for 15 min at 4°C. The pellet with synaptosomes was 
resuspended in 40 volumes of assay buffer containing 130mM NaCl, 1.3 mM 
KCl, 2.2mM  CaCl2*2H2O,  1.2mM MgSO4*7H2O,  1.2mM KH2PO4, 0.1mM  L-
Ascorbate, 10mM Glucose, 0.1mM Pargyline. 10 l of synaptosomes were 
stored at -20°C and use for protein determination. 100 l of synaptosomes (30-
40 g/well) were pre-warmed in a bath at the assay temperature of 37°C for 10 
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min and then incubated with vehicle (0.1% DMSO in assay buffer) or 
compounds  which were p38 MAP kinase activator, anisomycin (0.2-5 M), p38 
MAP kinase inhibitor, SB203580 (0.2-5 M)  or IL-1β (10-200ng/ml) for 5-30 min 
in assay buffer. 5HT uptake was initiated by adding 50µl of [3H]5HT (10-20nM 
final concentration) and after 5 min at 37°C, the reaction was stopped by rapid 
filtration as described in the protocol 1.  
Total counts obtained by filters were corrected for non specific signal obtained 
by parallel samples incubated with the selective SERT inhibitor Fluoxetine 
(10 M, Tocris). Analysis of protein concentration was performed by Bradford 
standard method.   
  
Section 2.2 Measurement of p38 MAP kinase phosphorylation in rat and 
mouse brain synaptosomes  
    
100 l of striatum or cortex synaptosomes were added to 400 l assay buffer 
(protocol 2) containing drugs and incubated in a bath at 37°C for 10-30 minutes. 
Samples were not standardized for protein. Synaptosomes were then 
centrifuged at 10000g for 20 min at 4°C, and pellet was re-suspended in 100µl 
1X Lysis buffer containing 20mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM 
Na2EDTA, 1mM EGTA, 1% Triton, 2.5mM Na4P2O7, 1mM β-Glycerophosphate, 
1mM Na3VO4, 1µg/ml Leupeptine. Samples were then kept on ice for 20 min, 
centrifuged 13000g for 20 minutes and than the supernatant was transferred in 
a new tube. 10µl was stored at -20°C and use for protein determination and the 
left solutionwas finally analysed in duplicate with phospho-p38 MAP Kinase 
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ELISA kit (Cell Signalling, Cat#7946) according to the instructions 
provided.Briefly, sample was diluted 1:1 with Sample Diluent (supplied in each 
PathScan® Sandwich ELISA Kit). 100μl of each diluted cell lysate was added to 
the appropriate well and incubate over night at 4°C. Plate was then washed four 
times with 1X Wash Buffer (200μl each time for each well) and incubates with 
Detection antibodies for 1 hour at 37°C. Each well was washed as described 
before and 100μl HRP-link secondary antibodies was the added for 30 min at 
37°C. Washes were repeated as before and 100μl of TMB substrate was added 
each well for 10 min at 37°C. Reaction was stopped by addition of 100μl Stop 
solution and adsorbance at 430nm was detected using spectrophotometer 
(SpectraMax, Molecular Devices).   
    
Section 2.3 Maintenance of HeLa, RBL2H3 and hSERT-LLCPK 
  
Hela cells (HeLa) and Rat basophilic leukemia cells, RBL2H3, have become 
readily accessible commercially and were received frozen in dry-ice from 
ECACC. Epithelial cell line from pig kidney (LLC-PK) expressing human SERT 
(hSERT-LLCPK) was kindly provided by GSK starting at passage 10. Cells 
were cultured in 75 cm2 tissue culture flask at 37°C in an atmosphere with 5% 
CO2, 100% relative humidity. All cells were grown in Dulbecco’s Modified 
Eagles Medium (DMEM, Gibco 41966-029) with 10% (v/v) foetal bovine serum 
(FBS) supplemented with 100 IU/ml penicillin and 100µg/ml streptomycin (HeLa 
and RBL-2H3) or 400µg/ml Hygromycin-B (LLCPK). To maintain healthy 
proliferation, the cells were routinely passaged every two days At approximately 
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100% confluency, media was aspirated off the cell monolayer and the cells 
washed in 5ml Phosphate-Buffered Saline (PBS; Sigma). Cells were then 
dissociated from a flask with 2 ml 0.05% Trypsin/EDTA solution (Gibco) for 2-5 
mins. The reaction was quenched with media containing 10% serum and spit in 
new flasks. All cell culture was completed in a microbiological safety cabinet, 
preventing contamination with bacteria, fungi and viruses. Before using cell in 
the assay, cells were cultured for at least two weeks in normal conditions (at 
least 4 passages) and then Hela cells and RBL2H3 were used between 
passage 4 and 8 and hSERT-LLCPK were used between passage 12 and 15.   
 
Section 2.4 Measurement of 5HT uptake in recombinant cell lines 
 
Cells were placed in 96-well plate one day before the experiment at the 
concentration of 20000 cell/well. After 24 hours, medium was aspirated and 
replaced with 100µl assay buffer (10mM HEPES, 130mM NaCl, 1.3mM KCl, 
2.2mM  CaCl2*2H2O,  1.2mM MgSO4*7H2O,  1.2mM KH2PO4, 0.1mM  L-
Ascorbate, 10mM Glucose, 0.1mM Pargyline) containing vehicle (0.1% DMSO 
in assay buffer) or compounds for 5-30 min at 37°C. 5HT uptake was initiated 
by adding 100µl of [3H]5HT (100 nM final concentration) and after 10 min at 
37°C, buffer was aspirated and cells were washed there times with ice-cold 
assay buffer. Cells were solubilised in 50µl Microscint 20 (PerkinElmer, cat# 
6013621) and radioactivity was counted with TopCount plate scintillation 
counter (PerkinElmer).   
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Section 2.5 Measurement of 5HT uptake in human blood platelets 
 
Human blood was collected in K3-EDTA tubes and centrifuged at 200xg for 10 
min at room temperature. The supernatant, that corresponds to platelet rich 
plasma (PRP) was collected and platelets were counted by flow cytometry and 
diluted in Krebs assay buffer (130mM NaCl, 1.3mM KCl, 2.2mM  CaCl2*2H2O,  
1.2mM MgSO4*7H2O,  1.2mM KH2PO4, 0.1mM  L-Ascorbate, 10mM Glucose, 
0.1m Pargyline) up to 20 million platelets /ml. 100 l assay buffer containing 
2x106 platelets were pre-warmed in a bath at 37°C for 10 min. 100µl assay 
buffer with vehicle (0.1% DMSO) or anisomycin was then added for 5-30 min.  
5HT uptake was initiated by adding 50 nM [3H]5HT and after 10 min, the 
reaction was stopped by rapid filtration through GF/B. Whatman paper washing 
three times with ice-cold assay buffer. Radioactivity was counted as described 
above.   
 
Section 2.6 Measurement of p38 MAP kinase phosphorylation in 
recombinant cell lines  
 
Cells were placed in 6-well plates one day before the experiment at the 
concentration of 1x106 cell/well. On the day of experiment, cells were treated 
with vehicle (DMSO final 0.1%) or compounds for 5-20 minutes in medium and 
then lysed with 100µl 1X Lysis buffer described above. In some experiment, 
cells were pre-treated with p38 MAPK inhibitor, SB203580 for 30 min before the 
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stimulation with drugs. All samples were then kept on ice for 20 min, centrifuged 
at 13000g for 20 minutes and finally analysed with phospho-p38 MAP Kinase 
ELISA kit (Cell Signalling) according to the instructions provided.  
 
Section 2.7 LPS treatment and sample preparation for the ex vivo 
experiment 
 
A intracerebroventricular cannula was implanted in Sprague Dawley rat 
(Charles river, 225-250g) to allow injection of LPS in the brain. After 1 week of 
recovery, rats were i.c.v. treated with vehicle (artificial cerebrospinal fluid, ACF, 
containing 125mM NaCl, 2.5mM KCl, 2.5mM MgCl2, 1.7mM CaCl2, 2mM 
Na2HPO4*7H2O) or LPS from Escherichia coli serotype 0111:B4 (20µg/dose in 
5µl ACF). After 2 hours, rat brains (four animals/group) were removed and cut 
into parasagittal halves. One half was dissected to prepare synaptosomes from 
cortex and striatum as described in the section 2.1 (protocol 1)Pre-frontal 
cortex, hippocampus and striatum were dissected from the other half, quickly 
frozen on dry ice and stored at -80°C to measure cytokine levels by multiplex 
technology (see section 2.7.1).  
 
Section 2.7.1 Assessment of cytokine level in the brain tissue by multiplex 
technology  
 
IL-1β, IL-6, IL-10, TNFα and IFN , levels were measured in cerebral 
homogenate with a Luminex instrument, using a multiplex suspension array 
technology. Basically, specific primary antibodies recognizing a cytokine are 
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conjugated with beads emitting different fluorescence. Once added to the 
samples, analyte and primary antibodies form immunocomplexes that are 
recognized as well by secondary antibodies (Detection antibody) which are 
coniugated with another fluorescent dye. The quantification was performed by 
the Luminex instruments, which identifies the type of beads and the 
fluorescence intensity of Detection antibody.  Concentrations were obtained 
from fluorescence values by comparison with a standard curve. The assay was 
carried out using Bioplex instruments (Biorad). Kit and reagents were 
purchased from Millipore (MILLIPLEX MAP Rat Cytokine/Chemokine Panel, cat 
N° RCYTO-80K). Brain tissues were placed in a tube and weighed.   5µl lysis 
buffer (Saniquin) for mg of tissue was added to the tube andthen samples were 
homogenized with minipestles, (Blu PP pestle Cod. Z359947 Sigma, Cordless 
motor Cod. Z359971 Sigma), incubated for 10 min on ice and centrifuged at 
13200 RPM at 4°C for 2 minutes. Supernatant was diluted 1:3 in assay buffer 
and 50µl/well were loaded on the kit plate in duplicate. The assay was 
performed following the instructions provided. Protein concentrations of 
samples were not detected and then cytokines concentration was not 
standarized to protein. Cytokines measured were IFN , TNFα, IL-1α, IL-1β, IL-6 
and IL-10.  
 
Section 2.8 Rat astrocytes preparation 
 
Rat cortical astrocytes were obtained from twelve 2-3 day old Sprague-Dawley 
pups. Rat brains were dissected out and placed in Petri dish with cold HBSSH 
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buffer (pH 7.3) containing 5mM potassium chloride (KCl), 0.44mM potassium 
phosphate monobasic anhydrous (KH2PO4 an.), 137mM sodium chloride 
(NaCl), 0.34mM sodium phosphate dibasic anhydrous (Na2HPO4 an), 4.2mM 
sodium bicarbonate (NaHCO3), 0.1% D-Glucose, 10mM Hepes, 100 U/ml 
penicillin and 100µg/ml Streptomycin. Under stereo microscope, peel off the 
meninges and transfer cortex to a tube containing cold HBSSH buffer. Cortices 
were minced with needle-sharp tweezers and transferred into three 50ml Falcon 
tubes containing 30ml of enzymatic dissociation solution (0.1% trypsin and 
0.02% DNase I type IV, D5025, Sigma). The tube was incubated for 20 min at 
37°C. After a centrifugation at 228g for 5 min, the pellet was filtrated through a 
cell strainer filter of 70µM (BD Falcon) into a new 50ml tube. Cells were 
centrifuged again and resuspended in medium 15% FBS (500ml of DMEM, 
75ml of FBS, 5ml of Pen/Strep, 2.2ml of Glucose).      
Cells were then placed in Poly-D-lysine (30000-70000) coated T175 flask 
(Nunc) for one night at 37°C, 5% CO2.  Medium was changed with new medium 
15% FBS at 2 days in vitro (DIV) and 10%FBS at 5 DIV. Rat astrocytes were 
detached with 0.05% trypsin plus 10mM EDTA, centrifuged and resuspended in 
freezing medium (DMEM, 15% FBS, 10% DMSO). Purity of culture was not 
detected. Aliquots were then stored at -80°C. Rat astyrocytes used in the assay 
were placed in 96 or 6-well plate at the density of 700-800 cells/mm2 and 
cultured for 12-14 DIV.    
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Section 2.8.1. Rat neuronal cultures preparation  
 
Cortical and hippocampal neuronal cultures were obtained from embryos at day 
18/19 of gestation (E18/19) of Sprague-Dawley rats. Rat brains were dissected 
out and hippocampi were quickly isolated at 4°C in HBSS pH 7.3 buffer 
containing 10mM Hepes, 100U/ml penicillin and 100µg/ml Streptomycin (HBSS 
buffer). Hippocampal and cortical cells were treated with HBSS buffer added 
with Trypsin 0.1% at 37°C for 10 min. In the last 5 min of incubation, cortical 
cells required an addition of 166µg/ml of DNAse I which facilates the cell 
dissociation. After a single wash with HBSSH buffer containing 10% FBS and 
two additional washes with HBSSH buffer, cells were mechanically dissociated 
by triturating with Pasteur pipets. Cells were than placed in Poly-L-lysine 
(P9404, MW >30000 kDa) coated 12- or 96-well plates at the density of 700-
800 cells/mm2 in serum-free Neurobasal medium supplemented with B27 
supplement, 500µM Glutamine, 100U/ml penicillin and 100µg/ml Streptomycin. 
In the hippocampal neurons, medium was supplemented with 12.5µM glutamate 
(Sigma, St. Louis, MO, USA). Cells were grown at 37°C, 5% CO2 and half the 
volume of the medium was changed after 4 days with complete medium without 
glutamate. In all assays, neuronal primary cultures were used after 8-10 days in 
culture. All reagents were purchased from Gibco/Invitrogen (Paisley, UK) except 
those in which supplier were indicated.   
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Section 2.8.2. Purity of cultured neuronal preparations 
 
Purity of cultured neuronal cells was assessed by immunoflorescence. Cells 
were grown on 12-well plate in coverslips at the density of 500 cell/mm2  under 
normal cultured conditions (see above).Onthe day of analysis the cells were 
processed at room temperature as described below.  Cultured medium was 
aspirated, washed once in a small volume of PBS buffer and then incubated for 
fixation in PBS containing 4% paraformaldehyde and 4% sucrose for 20 min. 
Cells were then washed for 5 min in PBS and then incubated in PBS with 5% 
FBS (quenching solution) for 30 min for blocking non-specific binding sites. In 
order to allow the permeabilization of antibodies, cells were incubated with PBS 
containing 0.1% Triton X-100 and 5% FBS for 10 min and then washed for 5 
min with quenching solution. Cells were incubated with astrocyte primary 
antibodies anti-GFAP (Sigma G9269, 1:1000, from rabbit) or neuron-specific 
nuclear protein primary antibodies anti-NeuN (Chemicon, MAB377, 1:200, from 
mouse) diluted in quenching solution for 1h, Unbound antibodies were eliminate 
by three washes of 5 min and then secondary antibodies anti-rabbit AlexaFluor 
594 (Molecular Probes/Invitrogen, 1:1000, from donkey) or anti-mouse 
AlexaFluor 488 (Molecular Probes/Invitrogen, 1:1000, from goat) was diluted in 
quenching solution and added for 45 min. After two washes with quenching 
solution and one with distilled water, coverslips were mounted with one drop of 
VECTASHIELD® Mounting Medium with DAPI (H-1200, Vector 
Laboratories,UK) and closed with nail polish. In order to quantify the purity of 
culture, 5 fields per coverslip are acquired using LEICA microscope (IM 50 
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program) and 20x objective. For each field, 3 pictures (blue, green and red 
channels) are acquired with the following parameter settings:  
 
DAPI (blu channel): exposure time 56.4 msec, gain/offset threshold: 26/1.17/6 
NeuN (green channel): exposure time 11 sec, gain/offset threshold: 22/1.10/9 
GFAP (red channel): exposure time: 1.1 sec, gain/offset threshold: 45/0.58/9 
 
The number of cells positive for each of the three markers was manually 
counted from the acquired pictures.     
 
Section 2.9. RNA extraction and quantification 
 
Total mRNA from primary neurons and astrocyte was extracted using RNeasy 
mini kit from Qiagen (Qiagen Inc, Valencia, CA, USA). Briefly, cells were grown 
in 12-well plate in normal conditions. Medium was aspirated and cells were 
washed two times with ice-cold PBS. 350μl RLT buffer was added to cells for 
the lysis. 350μl of 70% ethanol was added to cell lysate which was then putted 
in a RNeasy spin column.  Samples were centrifuged for 15sec at 10000xg. 
700μl Buffer RW1 was added to the RNeasy spin column and centrifuged for 
15sec at 10000xg to wash the spin column. The RNeasy spin column was 
washed two other times with Buffer RPE using the same procedure described 
previously and finally mRNA was eluated with 50μl Rnase-free water. Genomic 
DNA contaminants were removed from each samples using an RNAse-free 
Dnase I supplied by Applied Biosystem (Foster City, CA, USA). Briefly, samples 
43 
 
were incubated with RNAse-free Dnase I for 30min at 37°C. Samples were then 
centrifuged at 16000xg for 5 min and the pellet was resuspended in 50μl 
Rnase-free water. Purified RNA was quantified using an Agilent 2100 
Bioanalyzer following the Agilent RNA 6000 Nano kit protocol (Agilent 
Technologies Inc., Santa Clara, CA, USA). Briefly, the gel was prepared by 
mixing 65μl filtered gel with 1μl of dye and the tube was centrifuged at 13000Xg 
for 10 min at room temperature.9.0 μl of gel-dye mix was added to the RNA 
6000 Nano chip. 5 μl of RNA 6000 Nano marker was loaded in all sample wells 
following by 1μl of sample in each well. The chip was now ready to quantify the 
mRNA by the Agilent 2100 bioanalyzer within 5 min.  
 
Section 2.10 Reverse Transcribed PCR 
 
Complementary DNA (cDNA) was generated by reverse transcription of 100ng 
of total RNA using TaqMan Reverse Transcription Reagents (Applied 
Biosystem). The reaction consisted of 1X RT buffer, 2.5mM MgCl2, 1mM 
dNTPs, 2.5µM random hexamers, 0.4U/µl RNase Inhibitor, 1.25U/µl MultiScribe 
RT. The mixture was incubated consecutively at 25°C for 10 min, 48°C for 30 
min and finally 95°C for 5 min. PCR was carried out in a reaction volume of 30µl 
using HotStarTaq(R) PCR from Qiagen using this protocol: 10ng cDNA, 1X 
PCR buffer, 200µm dNTP’s, 300nM Primers, 1 unit Taq in Dnase-free water. 
After an initial incubation of 15 min at 95°C, 40 cycles of amplification were 
performed consisting of 30 sec denaturation at 95°C, 30 sec annealing at 60°C 
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and 40 sec extension at 72°C. The reaction was terminated with a final 
extension of 10 run  min at 72°C. Primer pairs were reported in Table 3.     
Table 3. Primers for 5HT7, 5HT6 and 5HT4 receptors  
Gene Sequence 
5HT7 
Forward: ATCTTCGGCCACTTCTTCTGCAACG 
Reverse: CAGCACAAACTCGGATCTCTCGGG 
5HT6 
Forward: CCATCTGCTTCACCTACTGC 
Reverse: TCTGAATCTGAGTTTGGCGG 
5HT4 
Forward: TTGGCTGCTTTGGTCTCTGTCCGC 
Reverse: TGCAAGGCTGGAACAACATCGGC 
    
PCR products were separated electrophoretically with 1.5% agarose gels. 
Agarose 1.5% in 1X TAE buffer (Tris 40mM, 1mM Glacial acetic acid, 0.1% 
EDTA pH 8) was heated in microwave until fully dissolved. After a brief cooling, 
a 1X SYBR safe DNA gel stain (Invitrogen) was added that binds to the DNA 
and allows visualization under UV illumination. Samples were mixed with a 6X 
DNA loading buffer composed by Bromofenol Blue 0.25% w/v, Xylene cyanol 
FF 0.25% w/v and Ficoll (Type 400) 15% and ran alongside DNA molecular 
weight markers (100bp ladder, Invitrogen) for 1 hour at 100V.      
 
Section 2.11 cAMP assay   
 
Intracellular cAMP accumulation was measured in neurons using cAMP Hi 
Range kit supplied by Cisbio (Bagnols-sur-Cèze, France). This assay is based 
on two fluorophores, a donor (Europium cryptate) and an acceptor (d2). 
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Excitation of the donor by an energy source (e.g. flash lamp or fluorometer 
laser) triggers an energy transfer to the acceptor if they are within a given 
proximity to each other. The acceptor in turn emits light at its given wavelength. 
This phenomenon is called FRET (Fluorescence Resonance Energy Transfer). 
In this specific case, the assay is a competitive immunoassay using cryptate-
labeled anti-cAMP and d2-labeled cAMP. When cAMP is present in solution, it 
displaces the d2-labeled cAMP determining a decrease of emit light. A standard 
curve with cAMP solutions of known concentrations is run in parallel.  The 
protocol described by suppliers was adapted to neurons cultured in adhesions. 
Neurons cultured in 96 well plates were incubated with vehicle (0.1% DMSO) or 
antagonists for 15 min at 37°C in medium before an addition of 5HT or forskolin 
(FSK) in the presence of 500µM 3,7-Dihydro-1-methyl-3-(2-methylpropyl)-1H-
purine-2,6-d ione (IBMX). After 30 min, medium was fully replaced with 100µl 
lysis buffer containing cryptate-labelled anti-cAMP and d2-labelled cAMP. After 
3 hours, europium cryptate fluorescence and time-resolved fluorescence 
emitted from acceptor  were measured 400µs after excitation at 340 nm at both 
615 and 665 nm using a Victor V fluorimeter (Perkin Elmer). Results were 
calculated from the 665nm / 620nm ratio and expressed in Delta F% following 
this equation:  
     
 
 
 
Sample ratio – Ratio neg
Ratio neg
DeltaF%=
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Where “sample ratio” was the 665nm/620nm ratio of each sample and “ratio 
neg” was the 665nm/620nm ratio calculated in wells where d2-labeled cAMP 
was not added. Sample cAMP concentrations were calculated from a standard 
curve.   
 
Section 2.12 Analysis of expression, phosphorylation and transport of 
expressed protein  
 
Section 2.12.1 Treatment and sample preparation  
 
Cultured neurons and astrocytes grown in 12-well or 6 well plates were treated 
with different compounds in medium at 37°C for the indicated time points. After 
a brief wash with ice-cold phosphate buffered saline (PBS, Invitrogen), cells 
were scraped into 100µl/well (12 well) or 200µl/well  (6 well) Lysis Buffer 
containing 10mM Tris (pH 7.4), 100mM NaCl, 1mM EDTA, 1mM EGTA, 1mM 
NaF, 20mM Na4P2O7, 2mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% 
Sodium dodecyl sulfate (SDS), 0.5% deoxycholate, 1mM 
phenylmethanesulfonyl fluoride (PMSF), one tablet of complete mini protease 
inhibitors (Roche, Indianapolis, IN, USA) and 1% phosphatase inhibitors I and II 
(Sigma). Cells lysates were transferred to tubes and kept at 4 °C for 30 min. 
Lysates were then centrifuged for 10 min at 13,000 x g, supernatants were 
transferred to new tubes and stored at -80°C. Samples were analysed by 
western blot to quantify total and phosphorylated protein expression (see 
section 2.12.4 and 2.12.5.).  
47 
 
Section 2.12.2.  Cell surface protein isolation  
 
Protein present at the cell surface can be purified using EZ-link sulfo-NHS-SS-
Biotin, a thiol-cleavable amine-reactive biotinylation reagent. Basically, this 
procedure uses a cell-impermeable, cleavable biotinylation reagent (Sulfo-NHS-
SS-Biotin) to label exposed primary amines of proteins on the surface of intact 
cells. Treated cells are then harvested, lysed and the labeled surface proteins 
are affinity-purified using the capacity of biotin to bind streptavidin and avidin 
with high specificity.   
In this biotinylation procedure, cultured neurons grown in 6-well plates were 
transferred onto a pre-chilled platform and all subsequent steps were conducted 
at 4ºC. Cells were washed with ice-cold PBS and then incubated for 20min with 
1mg/ml biotin (EZ-Link Sulfo-NHS-SS-Biotin; Pierce, Rockford, IL, USA) 
dissolved in PBS. After three rinses in ice-cold 50mM glycine in PBS to quench 
biotin, cells were rinsed in PBS and then scraped in 200µl/petri dish of 
homogenization buffer (0.1% SDS, 0.5% NP40, 0.5% sodium deoxicolate, 
150mM NaCl, complete mini protease inhibitors, phosphatase inhibitors cocktail 
I and II in PBS, pH 7.4). Homogenates were centrifuged at 10,000 x g for 20min 
to pellet the insoluble fraction. The supernatant (total extract) was analyzed for 
total protein content with a Micro BCA kit (Pierce). For purification of the 
biotinylated surface protein fraction, 50µg of total proteins were incubated with 
80µl of 50% slurry Neutravidin resin (Pierce) for 2h at 4ºC, by using spin 
columns with top and bottom caps. After washings with homogenization buffer 
(1min centrifugation of spin columns at 1,000 x g at 4ºC for three times), 
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biotinylated surface proteins were eluted by application of 100µl of elution buffer 
(Invitrogen NuPage LDS sample buffer 4x diluted to 1x with H2O and added 
with 50mM ditiothreitol as reducing agent) to the resin, heating at 95ºC for 5 
min, and centrifugation for 2min at 1,000 x g. Eluted fractions represented the 
purified biotinylated surface proteins (surface fraction) and were ready for gel 
loading (see section 2.12.4 and 2.12.5.). 
 
Section 2.12.3.  Protein sample quantification 
 
Section 2.12.3.1. Bradford standard method 
 
The protein concentration of samples was determined using Bio-rad reagent 
(Bio-Rad, UK) thet was based on an assay first described by Bradford in 1976 
(Bradford 1976, Anal Biochem. May 7;72:248-54. Bio-rad reagent was diluted 
1:5 with ddH20, and filtered through chromatography paper (Whatman, UK) to 
remove particulate matter. Bovine serum albumin (BSA) was diluted to 0, 0.2, 
0.4, 0.6, 0.8 and 1 mg/ml with H2O for use as protein standards. Filtered Bio-rad 
reagent (200µl) and 4µl of each sample were added to well of 96-well plate. The 
plate was mixed and incubated for 10 minutes at room temperature in a dark 
place. Coomassie® Brilliant Blue G-250, included within the reagent, shifts 
absorbance from 465 nm to 595 nm in the presence of protein. Absorbance was 
measured at 595 nm in a spectrophotometer (Spectramax 400) and BSA 
standards used to calculate a protein concentration/absorbance curve. Protein 
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concentration of each sample was calculated from the BSA standard curve, 
from the absorbance reading at 595 nm. 
Section 2.12.3.2. Micro BCA 
 
An alternative assay was used to determine protein concentration when protein 
concentration was very low or alternatively when small volumes were available. 
It was based on the micro BCA kit (Pierce). Micro BCA working reagent was 
prepared by mixing 25 parts of Micro BCA reagent MA, 24 parts Reagent MB 
with 1 part of Reagent MC. Bovine serum albumin (BSA) was diluted to 0, 0.7, 
1.5, 3, 6, 12, 25 and 50µg/ml with H2O for use as protein standards.  Micro BCA 
Reagent (150µl) and 150µl of each sample were added to a well of a 96-well 
plate. The plate was mixed and incubated for 2 hours at 37°C in a dark place.  
Bicinchoninic acid included within the reagent has a strong absorbance at 562 
nm in the presence of protein. Absorbance was measured then at 562 nm in a 
spectrophotometer and BSA standards used to calculate a protein 
concentration/absorbance curve as above.  
    
Section 2.12.4. Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
Protein were separated according to the molecular weight using  dodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).  The 
equipment used to run this assay was a XCell SureLock™ Mini-Cell (Invitrogen) 
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which allows SDS-PAGE to run in pre-cast mini-gels. The gels usedwere 1.5 
mm 4-12% Novex Bis-Tris Pre-Cast Mini Gels (Invitrogen). 
Equal amounts of cell lysates (~6-10µg protein) prepared in an equal volume of 
4X NuPAGE® LDS Sample Buffer and 10X NuPAGE® Sample Reducing 
Agent, were boiled for approximately 10 minutes, and centrifuged briefly to 
remove particulates prior to loading; 25-30µls for 10 well combs, 15-20µls for 15 
well combs. Prestained protein molecular weight markers (Novex® Sharp Pre-
stained Protein Standard) were loaded (10µl) to visualise migration, and identify 
approximate the molecular weight of protein bands. Electrophoresis was 
performed at 50V for 1 hour per gel.     
 
Section 2.12.5. Western blot  
 
To detect specific proteins resolved in polyacrylamide gels, polyclonal or 
monoclonal antibodies were used to label the antigenic region of the target 
protein. After separation, proteins were transferred to polyvinylidene difluoride 
membranes (Amersham plc., Buckinghamshire, UK) using a Mini Trans-Blot 
module (Bio-rad). Polyvinylidene fluoride (PVDF) was used during this study 
which can retain approximately 170µg protein/cm2 (Millipore). Pre-soaked fiber 
pads and correctly sized Whatman paper were stacked ensuring air bubbles did 
not form. One fiber pad, and one papers were layered, before polyacrylamide 
gel (soaked briefly in transfer buffer) was placed on the stack, followed by the 
PVDF membranes and one fiber pad and one Whatman papers. Proteins 
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transferred towards the anode; an optimal transfer required 40-50V for 
approximately 2 hour (see diagram below). 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
Table 4. Constituents of Western blot transfer buffer (stored at room temperature). 
 
Transfer Buffer pH 8.3 
Tris 25mM 
Glycine 192mM 
Methanol 20% 
Filter Paper 
Filter Paper 
SDS-PAGE Gel 
CATHODE (-) 
CATHODE (+) 
Transfer membranes 
Fiber pad 
Fiber pad 
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Before incubation with primary antibody, PVDF membrane was placed in 
blocking buffer, for approximately 1 hour at room temperature to reduce non-
specific background binding.  
 
 
 
 
Table 5. Constituents of Western blot wash buffer. N.B. 1 ml of Tween 20 was added to 
the 1 litre of 1x TBS to make TBS-T.  5% low-fat dry milk was added to TBS-T to make 
blocking buffer (stored at room temperature). 
 
Blocking buffer was Tris Buffered Saline (Table 5) added with 5% low fat 
skimmed milk and 0.1% Tween-20. Membranes were subsequently processed 
with primary antibodies rabbit anti-GluR1 Ser845P (Sigma A4477; 1:1000), 
rabbit anti-GluR1 (Millipore #04-855; 1:1000), rabbit anti-pan Cadherine 
(Abcam, Ab6528, dilution 1:1000) and mouse anti-GAPDH (SC-32233 from 
Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:10000). Membranes were 
washed three times in 0.1% Tween-20 in TBS (10 min every wash) and 
reincubated with the peroxidase-conjugated secondary antibodies goat anti-
rabbit IgG-HRP and goat anti-mouse IgG-HRP for 1 hour (both from Santa 
Cruz; 1:5000). The chemiluminescence reaction was developed with ECL Plus 
(Amersham) and detected with Luminescent Image Analyzer LAS-4000mini 
(Fujifilm, Tokyo, Japan). Optical densities were determined by densitometric 
10x Tris-Buffered Saline (TBS) 
pH 7.6 
Tris  0.5 M 
NaCl 2.8 M 
KCl 27 mM 
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analysis with Quantity One software (Bio-Rad Laboratories Inc., Hercules, 
California, USA).  
 
Section 2.12.6. Measurement of levels of total CREB, phospho CREB[133] 
and phospho p38 MAP kinase using ELISA kit 
 
Neurons cultured in 12 well plates were treated with antagonist or 0.1% DMSO 
for 15 min at 37°C in medium before the addition of agonist or forskolin. After 
stimulation, medium was aspirated and cells were scraped in to a lysis buffer 
containing 10mM Tris (pH 7.4), 100mM NaCl, 1mM EDTA, 1 mM EGTA, 1mM 
NaF, 20mM Na4P2O7, 2mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS, 
0.5% deoxycholate, 1mM PMSF, protease inhibitors (1 table in 10ml, ROCHE) 
and 1% phosphatase inhibitors I and II (Sigma). Cells lysates were transferred 
in tubes and kept at 4 °C for 30 min. Lysates were then centrifuged for 10 min at 
13000 g, supernatants were transferred into new tubes and stored at -80°C. 
ELISA kits were used to quantify total CREB and phospho CREB at serine 133 
were supplied by Invitrogen (Cat#KHO0241), while those used for phospho p38 
MAP kinase at tyrosine 180/182 were from Cell Signaling. Briefly, samples 
containing CREB [pS133] or CREB protein were diluted with Standard Diluent 
Buffer 1:10. Plates were covered and incubated 2 hours at room temperature. 
The liquid in each well was then aspirated following by four washings. After the 
addition of 100 μL of CREB [pS133] Detection Antibody solution into each well, 
the plate was incubated for 1 hour at room temperature. Liquid was aspirated 
and wells were washed as before. 100 μL Anti-Rabbit IgG HRP Working 
Solution was added to each well and incubated for 30 min at room temperature. 
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Liquid was aspirated and wells were washed as before. 100 μL of Stabilized 
Chromogen was added to each well and the liquid in the wells turned blue. After 
an incubation of 30 minutes at room temperature, in the dark, 100 μL of Stop 
Solution was added and absorbance of each well was read at 450 nm. Samples 
containing phospho p38 MAP kinase, were diluted with Sample Diluent Buffer 
1:10 and processed ad described in the section 2.2.   
 
Section 2.13. FLIPR/[Ca2+]i assay 
 
Intracellular Ca2+ ([Ca2+]i ) measurements were made using the FLIPR TETRA 
fluorescent imaging plate reader (Molecular Devices, Sunnyvale, CA). On the 
assay day, cultures were washed two times with Physiological Salt Solution 
(PSS; composition 145mM NaCl, 1g/L glucose, 5mM KCl, 2 mM CaCl2, 20mM 
HEPES) supplemented with 2.5mM probenecid (Sigma-Aldrich). Then, cells 
were added with the cytoplasmic calcium indicator, Fluo-4 (Invitrogen) in the 
acetoxylmethyl ester form (2μM) in PSS containing 5mM probenecid and 0.04% 
Pluronic F-127 (Sigma-Aldrich). After 40 min at 37 °C, cells were washed 3 
times as above and treated with compounds at 37 °C for different time points. 
When [Ca2+]i responses were measured, plates were transferred to the 
FLIPRTETRA equipped with a cooled CCD camera with excitation at 470–
495nM and emission at 515–575nM. Camera gain and intensity were adjusted 
for each plate to yield a minimum of 300 relative light units (RLU) baseline 
fluorescence. To assess the effect of 5HT and FSK receptor antagonists on the 
AMPA-triggered [Ca2+]i response, cultures were exposed to different 
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concentrations of 5HT and FSK for 10 min, then exposed to increasing 
concentrations of AMPA for 120s. Prior to addition of stimulators, 5 
fluorescence readings were taken to measure baseline. [Ca2+]i responses were 
quantified as area under the curve of the time-response data over baseline. 
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Section 2.14. Compounds  
 
Details of agonists and antagonists used across these assays were reported in 
the table below: 
*Tocris= Tocris Bioscience, Ellisville, MO, USA,  Sigma Aldrich= St. Luise, MO, USA 
 
Compunds Supplier* Catalog 
number 
Specificity Reference 
5HT Sigma-
Aldrich H9523 
Selective 5HT receptors 
agonist   
Mahe et al, 2004 
 SB258719 
Tocris, 2726 
Selective 5-HT7 antagonist Thomas et al., 1999 
GR113808 
Tocris 1322 
Potent and selective 5-HT4 
receptor antagonist 
Mikami et al., 2008 
SB399885 
Tocris 3189 
Potent and selective 5-HT6 
receptor antagonist pA2= 
7.85±0.04 
Hirst et al., 2007 
AS19 
Tocris 1968 
Potent 5-HT7 receptor 
agonist, IC50 = 9±1 nM 
Brenchat et al., 2009 
Anisomycin 
Tocris 1290 
Protein synthesis inhibitor 
(blocks translation). Potent 
activator of stress-
activated protein kinases 
(JNK/SAPK) and p38 MAP 
kinase  
Xiong et al., 2006 
SB203580 
Tocris 1402 
Selective inhibitor of p38 
MAP kinase  
Kumar et al., 1999 
Rolipram 
Tocris 0905 
Selective PDE4 inhibitor 
Selective inhibitor of cAMP 
phosphodiesterase PDE4,  
IC50 = 2.0 μM 
Teixeira et al., 1997 
Papaverine 
 
Sigma-
Aldrich P3510 
Unselective PDE10 
inhibitor 
Nihsi et al., 2008 
H89 
Tocris 2910 
Protein kinase A inhibitor 
that also inhibits several 
other kinases (IC50 values 
are 80, 120, 135, 270, 
2600 and 2800 nM for 
S6K1, MSK1, PKA, 
ROCKII, PKBα and 
MAPKAP-K1b). 
Chijiwa et al., 1989  
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Section 2.15. Data Analysis 
 
Statistical analysis of the data was performed using STATISTICA 8 (Statsoft, 
Inc., Tulsa, OK, USA). The model used to analyse uptake, ELISA and 
densitometry data was an ANOVA test analysis of variance in which the 
different treatment groups   were compared. These data were expressed as 
percentage or folds respect to the control.  As post hoc analysis, a Dunnett’s 
test was performed. In addition, when two groups needed to be compared, 
planned comparison of Least Squares means (LSD method) was performed. 
Transformation of average into square root was deemed necessary in order to 
improve compliance with normality assumption required for the mixed model. P-
values lower than 0.05 are considered statistically significant.  
 
Drug concentration-response curves from cAMP and FLIPR assay were fitted to 
a four parameter logistic equation using GraphPad Prism 5 (GraphPad Software 
Inc, San Diego, CA). Agonist potency was expressed as pEC50 (-log EC50). The 
inhibition of antagonists was expressed as the pIC50 (–logIC50), where IC50 
represents the concentration of drug inhibiting 50% of agonist maximal 
response. pKB values for antagonists were determined using the equation: pKB 
=(-log([antagonist]/(concentration ratio-1)) where concentration ratio = ratio of 
the agonist EC50 in the presence and in the absence of antagonist.  
 
 
58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
Chapter 3      Results 
 
 
Section 3.1 Effect of interleukin 1ß (IL-1ß) and p38 MAP kinase activator, 
anisomycin, on SERT function in rat cortex synaptosomes 
 
The assay adopted to measure if the pro-inflammatory cytokine IL-1ß could 
modulate the functionality of SERT in rat native tissue was an in vitro [3H]5HT 
uptake assay. This was performed in cerebral cortex synaptosomes due to the 
relatively high expression of SERT in this brain region, which improves the 
specific to non-specific signal. A basic pharmacological characterization of 
SERT was performed by measuring the uptake rate after incubation of 
increasing concentrations of 5HT. Cerebral cortex synaptosomes were 
prepared as described in protocol 1 (section 2.1), according to Thomas et al., 
(1987). The saturation curve fitted to a one-site hyperbola, giving Km and Vmax 
values of 37.2 ±6.0 nM (n=3) and 0.68 ± 0.11 fmol/µg/min (n=3), respectively 
(Figure 1).  
 
Figure 1. Representative saturation 5HT uptake curve on rat cerebral cortex 
synaptosomes.  The curve represents the specific [3H]5HT uptake measured in a 
single animal in triplicate. 5HT was incubated for 10 min before stopping reaction by 
rapid filtration Non specific uptake was identified by the addition of citalopram (10 µM). 
Experiment was replicated three times.  
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In order to verify if IL-1ß could modulate SERT function, 10 or 200 ng/ml IL-1ß 
were incubated with rat cerebral synaptosomes over incubation times of 10-30 
minutes and then [3H]5HT uptake rate was measured (figure 2). 
 
 
  
 
 
 
 
Figure 2. 5HT uptake on rat cortex synaptosomes in the presence of IL-1ß. (a) 
increasing concentrations of IL-1β (10, 200 ng/ml) incubated for 10 min. (b) 10 ng/ml 
IL-1β incubation at different end points (10, 20, 30 min). Values are expressed as the 
mean of three independent experiments  SEM (n=3; one-way ANOVA). 
 
 
Data analysis showed that IL-1ß did not produce any effect on 5HT uptake, 
suggesting that IL-1ß was not involved in the regulation of SERT function under 
these assay conditions. Since the activation of SERT seems to be mediated by 
p38 MAP kinase (Zhu et al., 2005), which is also a main mediator of cytokine 
responses (Roux and Blenis, 2004), a further study was performed using a 
direct activator of p38 MAP kinase, anisomycin; increasing concentrations of 
anisomycin in a range that showed an activation of 5HT uptake in previous 
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study (Zhu et al., 2004), were incubated for 5, 10, 20 minutes and impact upon 
[3H]5HT uptake was assessed.  
 
Figure 3. 5HT uptake on rat cortex synaptosomes in the presence of anisomycin  
incubated for different time periods. 0.2, 1, 5 µM anisomycin was incubated for 5, 
10, 20 min with synaptosomes before measuring 5HT uptake. Values are expressed as 
the mean  SEM of three experiments (n=3; one-way ANOVA). 
 
Graphs reported in Figure 3 showed that anisomycin did not produce any 
significant effect at all conditions tested. This finding was not in agreement with 
literature in which an activation of p38 MAP kinase induced by IL-1ß showed an 
increase of 5HT uptake in mouse synaptosomes (Zhu et. al. 2006). 
In an attempt to produce comparable data with those reported in the literature 
where SERT activation was observed, the experiments were replicated 
following the same experimental method (protocol 2, method section) described 
by Zhu et al., (2006). Moreover, in the literature, it was reported that inhibition of 
basal p38 MAP kinase activity induces SERT down-regulation in synaptosomes 
(Samuvel et al., 2005). In this group of experiments therefore, not only 
anisomycin but also the p38 MAP kinase inhibitor, SB203580, was assessed for 
impact on 5HT uptake.  
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Figure 4. 5HT uptake on rat cortex synaptosomes in the presence of anisomycin 
and SB203580 incubated at different end points. 0.2, 1, 5 µM anisomycin and 
SB203580 were incubated for 5, 10, 20 min with synaptosomes before measuring 5HT 
uptake. Values are expressed as the mean SEM of three experiments (n=3; one-way 
ANOVA; LSD method  Control Vs SB 5µM *P<0.05). 
 
No impact upon 5HT uptake, however, was identified by anisomycin incubation, 
confirming a lack of effect of p38 MAP kinase activation on SERT activity in rat 
cortex irrespective of the methodology used. In contrast, a slight but significant 
reduction of 5HT uptake was detected when SB203580 was tested at the 
concentration of 5 µM. This last piece of data was in agreement with literature 
results suggesting that constitutive activation of p38 MAP kinase may maintain 
SERT basal activity: hence when this activation was inhibited by SB203580 a 
reduction in SERT function was observed.    
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Section 3.1.1 Effect of anisomycin on 5HT uptake in mouse brain 
synaptosomes 
 
Rat brain synaptosomes treated with anisomycin did not show any modulation 
of SERT function. However, literature reported an increase of 5HT uptake rate 
when mouse brain synaptosomes were treated with anisomycin (Zhu et al., 
2007). In order to understand if the lack of effect was due to species differences 
in the modulation of SERT, the rate of 5HT uptake was also measured in mouse 
brain synaptosomes with or without anisomycin treatment, using identical assay 
conditions and brain areas (striatum, midbrain) as described (Zhu et al., 2007). 
 
Figure 5. 5HT uptake on mouse brain synaptosomes incubated with anisomycin 
at different end points. 0.2, 1, 5 µM anisomycin was incubated with synaptosomes for 
5, 10, 20 min before measuring 5HT uptake. Values are expressed as the mean±SEM 
of three experiments (n=3; one-way ANOVA) 
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No effect on 5HT uptake was detected in the presence of increasing 
concentrations of anisomycin in mouse synaptosomes with 5 to 20 min pre-
incubations (Figure 5). 
In the attempt to understand the reasons that led to the lack of effect of 
anisomycin or IL-1β on SERT function, further experiments were performed 
using striatal synaptosomes of individually-housed mice (Figure 6). These 
studies aimed to clarify if animal housing conditions, provoking a stress, could 
interfere with cytokine or anisomycin modulation of 5HT uptake. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 5HT uptake in synaptosomes of single housed mice pre-incubated with 
anisomycin at different end points. 1 µM anisomycin was incubated with 
synaptosomes for 5, 10, 20 min before measuring 5HT uptake. Values are expressed 
as the mean±SEM of three experiments (n=3; One-way ANOVA) 
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In these conditions, no significant effect on 5HT transport was observed as well 
suggesting that housing conditions did not influence the results.  
 
Section 3.1.2 Influence of interleukin 1ß and anisomycin on p38 MAP 
kinase activation in rat synaptosomes 
 
Data reported demonstrated that IL-1ß and p38 MAP kinase did not influence 
SERT function in rat and mouse synaptosomes. The activated form of p38 MAP 
kinase has a dual phosphorylation in two tyrosine residues (Tyr 180 and Tyr 
182). This form is able to phopshorylate and then activate a wide range of 
substrates that can be classified into protein kinases (MK2, MK3, MNK1/2, 
PRAK) and transcription factors (ATF1/2/6, Sap1, CHOP etc.). The level of 
activated p38 MAP kinase can be easily quantified by using specific antibodies 
that recognize this double phosphorylation. p38 MAPK activation has been 
shown to occur in response to extracellular stimuli such as UV light, heat, block 
of protein synthesis, osmotic shock, pro-inflammatory cytokines (TNF- & IL-1) 
and growth factors (CSF-1) (Roux PP and Blenis J, 2004). In order to assess if 
p38 MAP kinase could be activated in synaptosomal preparations, rat 
synaptosomes from cortex and striatum were incubated with IL-1ß (10 ng/ml) or 
anisomycin (1 µM) for 10, 20, 30 minutes and then phospho-p38 MAP kinase 
was quantified using an ELISA method. As a positive control, phospho-p38 
MAP kinase was also measured in HeLa cells treated with 50 ng/ml IL-1ß or 1 
µM anisomycin for 20 minutes. HeLa cells were recommended by the ELISA kit 
supplier as a cell line where anisomycin treatment results in high activation of 
p38 MAP kinase.  
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Figure 7. Measurement of phospho-p38 MAP kinase in rat synaptosomes from 
cortex (n=3) and striatum (n=2) treated with 1 µM anisomycin or 10 ng/ml IL-1ß over 
an incubation time of 10-30 minutes. Data are expressed as mean±SEM (cortical) or 
mean±range (striatal) of % activated p38 MAPK Vs control. No significant difference 
between samples (One-way ANOVA) 
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Figure 8. Measurement of phospho-p38 MAP kinase in HeLa cells treated with 1 
µM anisomycin or 50 ng/ml IL-1ß over an incubation time of 20 minutes (n=3). Values 
are expressed as average of % activated p38 MAPK Vs control. ***= p<0.001 Vs 
Control One-way Anova, Dunnett’s test). 
 
IL-1ß and anisomycin did not stimulate the activation of p38 MAP kinase in rat 
synaptosomes irrespective of the brain region or incubation time (figure 7). In 
contrast, HeLa cells treated with anisomycin or interleukin 1ß displayed 
enhanced levels of activated p38 MAP kinase, about 15 fold and 3 fold 
respectively, compared to control (figure 8). These data supported the 
hypothesis that in brain synaptosomes, p38 MAP kinase cannot be activated by 
IL-1ß or anisomycin under these conditions.  
 
Section 3.1.3 Lack of effect of anisomycin on 5HT uptake in human 
platelets 
 
5HT is expressed and released by many cells that belong to the CNS but also 
to the immune system. Human blood platelets represent an alternative 
biological system in which SERT is functionally expressed and can be 
modulated by anisomycin, as previously reported (Zhu et al., 2005). For this 
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reason, 5HT uptake was measured in human platelets incubated with 
increasing concentrations of anisomycin at different end points. (Figure 9) 
 
Figure 9. 5HT uptake on human platelets pre-incubated with anisomycin at 
different end points and concentrations. 1 µM anisomycin was incubated with 
synaptosomes for 5, 10, 20 min before measuring 5HT uptake. Values are expressed 
as the mean of two experiments performed in triplicate (n=3; one-way ANOVA). 
 
In agreement with results in brain synaptosomes, 5HT uptake rate was 
unmodified by anisomycin, suggesting that no modulation on SERT function in 
human platelets was associated with anisomycin treatment under these 
conditions. 
Section 3.1.4 Effect of anisomycin on 5HT uptake and p38 MAP kinase in 
rat and human cell lines expressing SERT   
 
Another system in which anisomycin has demonstrated a modulation of SERT 
function is in a rat basophilic leucemia (RBL-2H3) cell line (Zhu et al., 2005). 
These cells have a native expression of SERT and some stimuli activating p38 
MAP caused an increase in 5HT uptake. In order to understand if these cells 
responded to anisomycin with a SERT modulation, I reproduced the same 
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experiment using the same assay conditions. In parallel, anisomycin was also 
tested in a LLC-PK cell line expressing human SERT; where the high SERT 
expression could amplify small changes of transporter function induced by the 
kinase.  
Increasing concentration of anisomycin (0.2-5 µM) was incubated at different 
end-points and subsequently 5HT uptake and phosphorylation of p38 MAP 
kinase was measured. 
 
 
 
 
 
 
 
 
 
 
Figure 10. 5HT uptake on rat basophilic leukemia cells (RBL-2H3) and LLCPK 
expressing human SERT pre-incubated with anisomycin at different end points. 
Values are expressed as the mean of at least three experiments performed in triplicate 
(n=3; one-way ANOVA). 
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Anisomycin up to 5 µM did not show any effect upon both cell lines, thus 
confirming the absences of SERT modulation irrespective of the cell line used 
(figure 10). In contrast, anisomycin treatment induced a significant increase of 
p38 MAP kinase phopshorylation in hSERT-LLCPK cells after 30 min from 
addition. This effect was reversed by SB203580, confirming the specific 
activation of p38 MAP kinase when cells were incubated with anisomycin (figure 
11). 
 
 
 
 
 
Figure 11. Measurement of phospho-p38 MAP kinase in hSERT-LLCPK cells 
treated with anisomycin. a) 1 µM anisomycin was added over an incubation time of 
30 min. b) addition of 10 µM SB203580 for 30 min before the stimulation with 1 µM 
anisomycin for 30 min.  Values generated by three different experiments (n=3) are 
expressed as average of % activated p38 MAPK Vs control (*= p<0.05 Vs Control; 
#p<0.05 Vs 1 µM Anisomycin; One-way Anova, Dunnett’s test). 
 
This finding therefore highlighted that the lack of effect of anisomycin on 5HT 
uptake was not caused by the absence of p38 MAPK activation as it was 
reported in synaptosomes but it may be due to a lack of interaction between 
p38 MAPK and SERT  
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Section 3.2. Effect of LPS on SERT function in an ex-vivo experiment 
 
Data generated with the aim of demonstrating the effect of IL-1ß on SERT 
function through p38 MAP kinase were negative. However, this mechanism 
could be complex and tightly regulated so that a simplified in vitro system such 
as synaptosomes or isolated cells may have limited sensitivity. For this reason, 
a more physiological model was also investigated, in which an inflammatory 
response was induced directly in the intact brain avoiding tissue manipulation 
that could alter the interaction. The stimulation was performed by LPS, a potent 
activator of the inflammatory response that, when injected in the brain, 
produces a release of pro-inflammatory cytokines for a few hours (Roche et al., 
2006). This model is widely used to investigate the effect of neuroinflammation 
on brain function. Moreover, intraperitoneal administration of LPS stimulates an 
increase of activated p38 MAP kinase in rat cortex and hippocampus by the 
formation of reactive oxygen species (Nolan Y et. al., 2003).   Taken together 
these findings suggest that injection of LPS was a suitable intervention for the 
purpose of this study because it activates both cytokines and the p38 MAP 
kinase response.  
Rats were injected (i.c.v.) with vehicle (artificial cerebral spinal fluid; aCSF) or 
LPS (20ug/rat) and after two hours, animals were killed and the cerebral cortex, 
striatum and hippocampus harvested. These tissues were then used to prepare 
synaptosomes and subsequently 5HT uptake parameters Km and Vmax rate 
were assessed between treated and control animals. In order to confirm that 
LPS injection evoked a cytokine release, part of the brain tissues were analysed 
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by Luminex technology to determine the level of IFN , TNFα, IL-1α, IL-1β, IL-6, 
and IL-10.     
Animals treated with LPS revealed a [3H]5HT uptake with Km and Vmax values of 
102.2±19.5 nM and 20.7±2 pmol/min/mg, respectively, in striatum and 34.8±1.9 
nM and 7.8±0.7 pmol/min/mg, respectively, in cortex.  Animals treated with 
vehicle showed Km and Vmax values of 118.5±27.9 µM and 24.1±6.7 
pmol/min/mg in striatum and 33.2±1.1 nM and 7.3±0.4 pmol/min/mg in cortex 
(Figure 12).  Comparison of uptake parameters between the two groups 
revealed no significant differences, suggesting no change of 5HT uptake rate 
(Student’s t-Test). However, LPS administration caused considerably higher 
levels of interleukin 1α and TNFα in comparison to vehicle treatment in striatum, 
cerebral cortex and hippocampus. Interleukin 1ß and IL-6 were also significantly 
increased in cortex and in hippocampus. In contrast, interleukin 10 and 
interferon-γ levels did not undergo any significant change in any region 
investigated (Table 6). Overall, these data revealed that SERT function was not 
changed in a rat intact brain system during central exposure to inflammatory 
mediators.           
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Figure 12. 5HT uptake on rat synaptosomes in animals treated with vehicle or 
LPS (i.c.v. 20 µg/rat). Each curve represents the specific [3H]5HT uptake measured in 
a single animal. Values are expressed as the mean±sem of three uptake 
measurements. 
 
 
 Striatum Cortex Hippo 
 Vehicle LPS Vehicle LPS Vehicle LPS 
IL-1α 228±86 2028 ±1057# 103±22 1428±404** 226±116 2188±629** 
IL-1ß 668±123 1402±468 602±41 1049±128** 671±121 1559±306* 
IL-6 690±26 787±61 528±38 684±61# 659±37 1005±92** 
TNFα 56±8 284±132# 33±2 262±72** 40±5 412±129** 
IFN  70±16 75±7 41±4 49±2 56±2 53±2 
IL-10 530±49 519±4.2 392±35 432±23 409±29 363±39 
  #p<0.06, *p<0.05, **p<0.01 Vs Vehicle  
Table 6. Comparison of cytokine levels between animals treated with vehicle and LPS.  
Values are expressed as mean±sem of pg/ml cytokines measured in the brain tissue of 
four animals per group (n=4; Student’s T-test).         
 
 
Section 3.3 Expression of 5HT7 receptors in rat cortical astrocytes and 
activation of p38 MAP kinase 
 
Studies reported in the previous sections indicate that the p38 MAP kinase 
activator, anisomycin, and the pro-inflammatory cytokine, interleukin-1ß, do not 
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produce an activation of 5HT uptake in rat and mouse brain, suggesting that 
SERT function is not altered by inflammatory processes involving p38 MAP 
kinase. 5HT itself regulates serotonergic transmission in the CNS through a 
number of auto- and hetero-receptors (Barnes & Sharp, 1999). One such 
receptor involved not only in the serotonergic transmission but also in the 
regulation of neuroinflammation appears to be the 5HT7 receptor. Some 
investigations have reported that 5HT7 regulates p38 MAPK activation and 
consequently cytokine release in human U-373 astrocytoma cells (Lieb et al., 
2005). This mechanism seems present also in human microglia cells where 
5HT7 receptors regulate IL-6 release (Mahe et. al. 2004). Taken together, it 
would seem that pro-inflammatory cytokines via p38 MAP kinase mechanisms 
can be regulated by 5HT7 receptors, providing a plausible mechanistic link 
between the immune and serotonergic systems. Experiments described in this 
section aimed to establish the presence of 5HT7 receptors in rat cortical 
astrocytes and, if their activation produced an increase of cAMP with a 
consequent activation of p38 MAP kinase, the release of cytokines was 
assessed.   
 
Section 3.3.1 Increase of intracellular cAMP induced by 5HT7 receptors in 
rat cortical astrocytes  
 
Since 5HT7 receptor is positively coupled with Gs proteins, its activation 
stimulates an increase of intracellular cyclic adenosine monophosphate (cAMP) 
through adenylate cyclase (AC) activation. This phenomenon was reported in 
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various recombinant cell systems transfected with human and rat 5HT7 
receptors (Mahé C et al., 2004; Romero G et al., 2006). Indeed previous 
investigations showed that 5HT induced an increase of cAMP in 
thalamic/hypothalamic rat astrocytes while no response was detected in cortex 
and cerebellum, suggesting no expression of 5HT7 receptors in these two 
areas. However further PCR analysis revealed the presence of mRNA for 5HT6 
and 5HT7 receptors in cortex suggesting the expression of 5HT7 receptors in 
cortex that was too weak to be detected (Hirst WD et al., 1997). The use of a 
specific assay based on Fluorescence Resonance Energy Transfer (FRET) 
technology could increase the sensitivity to quantify cAMP at low 
concentrations. Therefore, to confirm the presence of 5HT7 receptors in plasma 
membranes of rat cortical astrocytes, a measurement of intracellular cAMP was 
performed with this method. Rat cortical astrocytes were obtained from 2-3 day 
old pups following the procedure described in the “material and methods” in 
section 2.8. Previous investigations showed 5HT7 receptors expression in 
astrocytes after 12 days in vitro and therefore cells were plated in 96-well plates 
and cultured for 15 days in normal condition before running the assay (Hirst WD 
et al., 1997). Since FBS could interfere with 5HT receptor expression due to the 
presence of serotonin, cells were cultured in normal medium and in dialysed 
FBS medium. Moreover, cells cultured in normal medium were also kept in 
FBS-free medium for 24 hours before running the assay.  
The specificity of signal was assessed using the selective 5HT7 receptor 
antagonist, SB258719. Cells were treated with 10 µM SB258719 for 15 min at 
37°C before the addition of 1 µM 5HT. As positive control, cells were treated in 
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parallel with 1 µM forskolin. After 30 min, cells were lysed and cAMP 
concentration was measured.    
 
 
Figure 13. Measurement of intracellular cAMP in rat cortical astrocytes. Cells were 
treated with 10 µM SB258719 (ant) prior to stimulation with 1 µM 5HT for 30 min . As 
positive control, 10 µM forskolin (FSK) was also tested.  Data were the mean ± SEM of 
three individual experiments (n=3). Results are expressed as % response vs. basal 
cAMP levels (one-way ANOVA; Dunnett’s test *p<0.05).    
 
Rat cortical astrocytes treated with 5HT showed a significant increase in cAMP 
levels when cells were cultured in medium without FBS or with dialysed FBS; 
increase of 178±33% and 131±13% vs. basal, respectively. No effect was 
observed in normal 10% FBS medium, conforming the impact of FBS on the 
5HT receptor response.  FSK increased cAMP levels across all conditions, as 
expected. SB258719 (10 µM) reversed completely the effect of 5HT, confirming 
that this response was mediated by 5HT7 receptors. Culturing cells for 24 hours 
in the absence of FBS gave a higher cAMP increase, demonstrating a better 
response of 5HT7 receptors under this condition (figure 13). 
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Section 3.3.2. p38 MAP kinase phosphorylation and interaction with 5HT7 
receptors in rat cortical astrocytes  
 
On confirmation of the expression of 5HT7 receptors in rat cultured astrocytes, 
the interaction between p38 MAP kinase and 5HT7 receptors was investigated 
by measuring specific p38 MAP kinase phosphorylation after 5HT stimulation. 
Rat astrocytes cultured for 15 days and kept in FBS-free medium for 24 hours 
were pre-treated with SB258719 for 15 min at 37°C and then 1 µM 5HT was 
added. Cells were lysated after 5 min and the amount of phosphorylated p38 
MAP kinase was quantified using a specific ELISA assay. 
 
   
Figure 14. Effect of 5HT on p38 MAP kinase phosphorylation on rat astrocytes. 
Cells were treated with 10 µM SB258719 for 10 min before stimulation with 1 µM 5HT 
for 5 min.  Data were the mean ± SEM of at least seven individual experiments (n=7; 
one-way ANOVA followed by post-hoc comparisons (LSD method) between Basal Vs 
5HT and 5HT Vs SB+5HT; *p<0.05 Vs Basal; #p=0.05 Vs 5HT).    
 
Rat astrocytes showed a significant increase of p38 MAP kinase 
phosphorylation after 1 µM 5HT addition and the effect was reversed by 10 µM 
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SB258719 (figure 14). These findings revealed an interaction between 5HT7 
receptors and p38 MAP kinase not only in astrocytoma and microglia as 
previous reported in the literature (Lieb et al., 2005; Mahe et al., 2004) but also 
in cultured astrocytes, supporting the role of 5HT via 5HT7 receptors in the 
regulation of brain inflammation. 
 
Section 3.4 Expression of 5HT7 receptors in hippocampal and cortical 
neurons 
 
The interaction between 5HT7 receptors and p38 MAP kinase in rat astrocytes 
supports the hypothesis of a role of 5HT7 receptors in the regulation of neuro-
inflammation. The literature reported that this interaction was observed in 
microglia cells and in astrocytomas and the current study confirmed this 
mechanism in rat astrocytes. 5HT7 receptors are also expressed in neurons 
expecially in hippocampus  with a link to neuronal excitability (Tokarski el al., 
2003) and LTP (Roberts AJ et al., 2004). However, no data have been reported 
on the interaction between 5HT7 receptors and p38 MAP kinase in neurons and 
if this mechanism may be linked with neurotrasmission. Therefore, this potential 
interaction was investigated in rat primary neurons obtained from rat 
hippocampus and cortex. In order to obtain a pure culture of neurons, rat 
embryos at day 18/19 of gestationwere used according to the procedure 
described in “materials and methods” section. The purity of the rat primary 
neurons cultures after 8-10 days in vitro was evaluated using the neuronal 
marker NeuN, the astrocyte marker, GFAP and the general nuclear marker, 
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DAPI. The percentage of cortical NeuN and GFAP positive cells vs DAPI cells 
was 66% and  1.7% respectively while the percentage of hippocampal NeuN 
and GFAP positive cells vs DAPI was 78.3% and 10.2% respectively.  
In these brain regions, serotonergic neurons express different subtypes of 5HT 
receptor.  Oligonucleotides recognising the sequence of 5HT7, 5HT4, 5HT6 
receptor transcripts were used to investigate expression of Gs-protein coupled 
5HT receptors subtypes. 
Neurons were grown for 8-10 days in normal medium at 37°C, 5% CO2 and 
then total mRNA was extracted and analysed by RT-PCR. Positive controls 
represented amplification of cDNA obtained from hippocampus of adult rat brain 
and negative controls represented an amplification of cDNA from cultured 
neurons in which the RT enzyme was excluded from the reverse transcriptase 
step. Data revealed that negative controls did not result in any product, thus 
confirming the absence of DNA from genome or other non-specific 
contaminations.  PCR products of positive controls and both cultured 
hippocampal and cortical neurons yielded bands of the correct size 
corresponding to 5HT7, 5HT4 and 5HT6 receptors’ cDNA (Figure 15).    
80 
 
 
Figure 15. Representative reverse transcriptase PCR of cDNA from adult rat 
hippocampus (lanes 5,6,11,12,17 and 18) and cultured neurons obtained from 
hippocampus (lanes 3,4,9,10, 15 and 16) and cortex (lanes 1,2,7,8, 13 and 14) of 
E18/19 rat embryos. Primers specific for 5HT7 receptor gene (lanes 1-6), 5HT4 receptor 
gene (lanes 7-12) and 5HT6 receptor gene (lanes 13-18) were used to amplify DNA 
fragments of 850, 303 and 538 bp respectively. Lanes 2,4,6,8,10,12,14,16,18 show 
negative controls where the RT enzyme was excluded from the RT step.  Each line of 
ladder (M) represents a band size of 100 bp. Identical results were obtained by three 
independent neurons preparations (n=3).   
 
Although PCR is not a quantitative analysis of mRNA expression, this piece of 
data confirms the presence of mRNA for 5HT7, 5HT4 and 5HT6 receptors in 
cortical and hippocampal primary neurons. The characterization of functional 
5HT7 receptor expression in membranes was assessed subsequently.  
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Section 3.4.1 Characterization of 5HT7 response in cortical and 
hippocampal embryonic derived neurons by measuring intracellular cAMP 
levels 
 
In order to verify if 5HT receptors coupled to Gs protein were functionally 
expressed in cortical and hippocampal embryonic derived neurons, intracellular 
cAMP concentration was measured in neurons after treatment with 5HT (1 µM) 
for 30 minutes. In parallel, neurons were also treated for 30 minutes with 
Forskolin (10 µM), a potent activator of adenylate cyclase.  
 
 
 
Cortical neurons did not show a robust response to 5HT, while an increase in 
cAMP levels of about 1618±140% compared to the basal level was measured 
Figure 16. Measurement of intracellular cAMP in cortical and hippocampal 
neurons stimulated with 5HT (1 µM) or forskolin (10 µM) for 30 min. Data are 
the mean ± SEM of three individual experiments (n=3). Results are expressed as 
% response vs. basal cAMP levels (one way ANOVA, Dunnett’s test; **p<0.01, 
***p<0.001).    
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after forskolin treatment. Hippocampal neurons displayed a consistent response 
when treated with 5HT or with forskolin and the increase of intracellular cAMP 
vs. basal levels was 145±15% and 1462±324%, respectively (Figure 16, one-
way ANOVA, response vs. basal, **P<0.01, ***P<0.001). This result indicated 
that cortical neurons did not express detectable functional 5HT receptors 
coupled to adenylate cyclase, although a considerable mRNA expression was 
detected, while hippocampal neurons expressed 5HT receptors able to increase 
intracellular cAMP.  
The presence of 5HT receptors in hippocampal neurons was further 
investigated by measuring cAMP levels after treatment with increasing 
concentrations of 5HT for 30 min. 5HT showed a concentration-dependent 
increase of cAMP. Data was fitted to a four-parameter logistic equation giving a 
pEC50 of 7.2±0.2 and Hill slope of 1.2±0.2  The maximal response to 5HT was 
an increase of cAMP of 180% compared to basal levels (Figure 17).  
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Figure 17. Concentration-response curve to 5HT in hippocampal cultured 
neurons. Hippocampal cultured neurons were treated with increasing concentrations 
of 5HT (10 µM-0.1nM). Intracellular cAMP was measured 30 min after addition. Data 
were generated in three different experiments (n=3) and represent the percentage of 
accumulated cAMP±SEM vs. basal levels.   
      
In order to understand which Gs protein-coupled 5HT receptors were involved 
in this response, the selective 5HT7 receptor antagonist SB258719, the 5HT4 
receptor antagonist SB399885 and the 5HT6 receptor antagonist GR113808 
were tested. cAMP increase induced by 5HT (0.1 µM) was fully reversed by 
SB258719, with a pIC50 of 7.95 ±0.09 (n=3). In contrast, the selective 
antagonists SB399885 and GR113808 (either at 1 µM) did not reverse 5HT 
impact upon cAMP levels, suggesting that cAMP increase induced by 5HT was 
principally mediated by 5HT7 receptors (Figure 18). The selective 5HT7 receptor 
antagonist SB258719 also antagonized in an apparently competitive manner 
the response to 5HT with a pKb of 8.23±0.1 (Figure 19), confirming a profile of 
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competitive antagonism for this compound, as previously observed (Thomas et 
al., 1999).   
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 Effect of selective 5HT receptor subtype antagonists SB258719 (5HT7), 
SB399885 (5HT4) and GR113808 (5HT6) on the increase of cAMP levels induced 
by 5HT. Hippocampal neurons were treated with  antagonists for 15 min followed by 
the addition of 0.1 µM 5HT. Intracellular cAMP was measured 30 min after agonist 
addition. Data were generated by three different experiments (n=3) and represent the 
percentage of increase of cAMP±SEM after 5HT addition.   
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Figure 19. Concentration-response curve of 5HT alone and in the presence of 
SB258719. Hippocampal cultured neurons were treated 15 min with 100nM SB258719 
before the stimulation with 5HT. Data were generated by three different experiments 
(n=3) and represent the percentage of accumulated cAMP±SEM vs. basal levels.        
 
 
 
Section 3.4.2 Influence of 5HT7 receptors on CREB expression and 
phosphorylation in hippocampal neurons 
 
One of the most relevant effects following an increase of intracellular cAMP is 
the phosphorylation of CREB at serine 133 (CREB[133]), which is necessary for 
the activation of CRE-dependent gene expression. In order to evaluate if the 
increase of cAMP induced by 5HT7 receptors is translated in a signal 
transduction pathways, the phosphorylation of CREB was evaluated. Cultures 
were treated with 1 µM 5HT at different time points ranging between 5 and 60 
min. In parallel, cultures were also incubated with 10 µM forskolin for 30 min. 
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After treatment, cells were lysed and the amount of phospho-CREB[133] and 
total CREB were measured using ELISA assays.  
The time course analysis of 5HT response showed a significant increase of 
phospho-CREB[133] of about 168±23% vs. basal 5 min after addition. This 
signal was transient and returned to basal level after 10 min. Forskolin also 
induced an increase of CREB phosphorylation of about 193±7% vs. basal levels 
30 min after addition (Figure 20).                  
 
   
 
Figure 20. Effect of 5HT on CREB phosphorylation at different time points. 5HT 
was added to cultures for different incubation times (5, 10, 30, 60 min) and then the 
amounts of phospho CREB[133] and total CREB were measured using an ELISA 
assay. 10 µM forskolin incubated for 30 min was used as control. Data were the 
mean±SEM. of three different experiments (n=3) and represent the pCREB[133]/ total 
CREB ratio of treated neurons vs. basal (one-way ANOVA; Dunnett’s test.  *p<0.05 Vs 
Basal).  
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In order to investigate if the increase of CREB phosphorylation induced by 5HT 
was mediated by 5HT7 receptors, cultured hippocampal neurons were treated 
for 15 min with increasing concentrations of the 5HT7 antagonist SB258719 
prior to stimulation with 1 µM 5HT for 5 min. Data analysis revealed that 
SB258719 significantly reduced CREB phosphorylation induced by 5HT in a 
concentration-dependent manner confirming the mediation of 5HT7 receptors 
(Figure 21). Interestingly, SB258719 did not reverse completely the 5HT 
response even at 10 µM although the calculated inhibition of 10 µM SB258719 
should be around the 99% (value extrapolated by pKb generated in the cAMP 
assay).   
 
   
Figure 21. Effect of the selective 5HT7 antagonist SB258719 on CREB 
phosphorylation induced by 5HT. Cultured neurons were treated with SB258719 for 
15 min and then 1 µM 5HT was added for 5 min. The amount of phospho CREB[133] 
and total CREB were then measured using ELISA assays. Data were the mean±SEM 
of three different experiments (n=3) and represent the pCREB[133]/ total CREB ratio of 
treated neurons vs. basal (one-way ANOVA; post doc comparison (LSD method) Vs 
Basal and Vs 5HT. *p<0.05 Vs Basal, #p<0.05 Vs 1 µM5HT).  
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Section 3.5  Influence of 5HT7 receptors on p38 MAPK expression and 
phosphorylation in hippocampal neurons 
 
Once the pharmacological characterization of 5HT7 receptors in hippocampal 
cultured neurons was completed, the interaction between 5HT7 receptors and 
p38 MAP kinase in hippocampal neurons was investigated. Hippocampal 
neurons were treated with 1 µM 5HT at different end points ranging between 5 
and 60 min. In parallel, cells were also treated with Forskolin for 30min as 
positive control. Cells were then lysated and the amount of phosphorylated p38 
MAP kinase was quantified using an ELISA assay.  
 
Figure 22. Effect of 5HT on p38 MAP kinase phosphorylation at different time 
points. 5HT was added to cultured neurons for various incubation times (5, 10, 30, 60 
min) and then the amount of phospho p38 MAP kinase was measured using an ELISA 
assay. In parallel, neurons were treated with 10 µM forskolin incubated for 30 min. Data 
were the mean±SEM of three different experiments (n=3) and represent the percentage 
of response vs. basal levels (one-way ANOVA).  
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Data showed that neither 5HT nor Forskolin (FSK) changed the level of 
phospho p38 MAP kinase at any of the tested time points, suggesting that 
although 5HT7 receptors are expressed in hippocampal neurons and produce a 
functional response (increase of cAMP level and CREB phosphorylation), they 
do not interact with p38 MAP kinase under these conditions (Figure 22).      
 
Section 3.6 Influence of 5HT7 receptors on GluR1 expression and its post-
translational modification 
 
The fact that 5HT7 receptors do not interact with p38 MAP kinase in neurons 
suggests a cell-dependent function of 5HT7 receptors with a different role in 
neurons compared to that observed in astrocytes. The presence of 5HT7 
receptors in hippocampus was previously described as a regulator of synaptic 
transmission (LTP) and neuronal excitability (Tokarski el al., 2003). Synaptic 
strength is tightly regulated by the phosphorylation of GluR1 receptors 
(AMPAR) and their cellular distribution (Santos et al., 2009). Basically, AMPA 
receptors are formed by different subunits which are encoded by four genes 
(such as GluR1, GluR2, GluR3, and GluR4, Hollmann, and Heinemann, 1994). 
Hippocampal neurons expressed mainly GluR1, GluR2 and GluR3 and the 
preferred configurations were two identical heterodimers of GluR1/2 and 
GluR2/3. When AMPAR received the stimulus, GluR1 was phosphorylated at 
multiple sites (Ser831, Ser845 etc) and this determined a migration of AMPAR 
to the synapses. The amount of AMPARs at the level of synapses determined 
the modulation of glutamatergic transmission.         
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In order to understand if 5HT7 receptors may affect GluR1 phosphorylation or 
expression in hippocampal neurons, cultures were treated with 1 µM 5HT or 10 
µM FSK for 5 min. Cells were lysed and proteins in the extract were separated 
by SDS-PAGE.  Immunoblot analysis was then performed with antibodies that 
recognize phopshorylated GluR1 at Ser845, GluR1 and GAPDH.  
 
 
 
 
 
 
 
 
 
Figure 23 Effect of 5HT and FSK on phopshorylated GluR1 at Ser 845 and total 
GluR1 in primary hippocampal neurons. (a) Representative western blot of neurons 
treated with 5HT and FSK for 5 min. Cells extracts were analysed with anti-
phosphoGluR1(845), anti-GluR1, and anti-GAPDH antibodies. (b-c-d) Quantification of 
phosphorylated GluR1(Ser845) and total GluR1. Ratio of GluR1(Ser845P)/GAPDH, 
totGluR1/GAPDH and GluR1(Ser845P)/totGluR1 are expressed as fold increase±SEM. 
with respect to basal levels in three different experiments (n=3; ANOVA followed by 
post hoc comparisons (LSD method) Vs basal *P<0.05 vs. Basal). 
 
 
GluR1 Ser845P
GAPDH
Tot GluR1 
tot GluR1
GAPDH
tot GluR1
GAPDH
tot GluR1
GAPDH
ba
sa
l
1µ
M
 5
H
T
10
 µ
M
 F
SK
0
20
40
60
80
*
*
G
lu
R
1
 S
e
r8
4
5
P
/G
A
P
D
H
(f
o
ld
 V
s
 b
a
s
a
l 
le
v
e
l)
ba
sa
l
1µ
M
 5
H
T
10
 µ
M
 F
SK
0
1
2
3
4
5
*
*
T
o
ta
l 
G
lu
R
1
/G
A
P
D
H
(f
o
ld
 V
s
 b
a
s
a
l 
le
v
e
l)
ba
sa
l
1µ
M
 5
H
T
10
 µ
M
 F
S
K
0
10
20
30
*
*
G
lu
R
1
 S
e
r8
4
5
P
/t
o
ta
l 
G
lu
R
1
(f
o
ld
 V
s
 b
a
s
a
l 
le
v
e
l)
a 
b c d 
91 
 
These experiments showed that both 5HT and FSK significantly increased the 
amount of phosphorylated GluR1 by about 14.7±1.7 and 42.7.1±14.9 fold 
compared to basal levels. Moreover, both compounds induced an increase of 
total GluR1 of 1.73±0.5 and 2.8±1.7 compared to basal levels, respectively. The 
graph in figure 23d represents the ratio between phosphorylated and total 
GluR1 reflected the data reported above.  
Since the PCR analysis suggested that different kinds of 5HT receptors were 
expressed under these conditions, a further group of experiments was 
performed to assess if this effect was specific to the activation of 5HT7 
receptors.  
Before the stimulation with 1 µM 5HT for 5 min, neurons were treated with 
increasing concentrations of different classes of 5HT antagonists (the selective 
5HT7 receptor antagonist SB258719, the selective 5HT4 receptor antagonist 
GR113808 and the selective 5HT6 receptor antagonist SB399885) for 15 min 
and then analysis of phosphorylated GluR1 expression was performed. In 
addition, neurons were also treated with the selective 5HT7 receptor partial 
agonist, AS-19 (1 µM) for 5 min in the presence or in the absence of 10 µM 
SB258719 pre-incubation as above. 
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Figure 24 Effect of agonists and antagonists of 5HT receptor subtype es on 
phosphorylated GluR1 at Ser 842 and total GluR1. (a) Representative western blot 
of neurons treated for 15 min with vehicle (DMSO 0.1%), 1 µM SB399885 (5HT6 ant.), 
1 µM GR113808 (5HT4 ant.) or 10 µM SB258719 (5HT7 ant.) followed by treatment with 
1 µM 5HT (left hand panel) or 1 µM AS19 (right hand panel) for 5 min. (b-c) 
Quantification of phosphorylated GluR1(Ser845) and total GluR1. Ratio of 
GluR1(Ser845P)/GAPDH, totGluR1/GAPDH and GluR1(Ser845P)/totGluR1 are 
expressed as fold increase±SEM with respect to basal levels in three different 
experiments (n=3; ANOVA followed by post hoc comparisons (LSD method) Vs basal 
Vs 5HT or AS-19, . *P<0.05 vs. Basal; #p<0.05 Vs 1 µM 5HT or AS-19;  
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These data revealed an increase of GluR1 phosphorylation when 5HT was 
added (11.6 ±1.1 fold vs basal) and this effect was not changed by GR113808 
(13.1 ±2.4 fold vs basal) nor SB399885 (14.4 ±2.4 fold vs. basal), while it was 
reversed by SB258719 (5.3 ±1.2 fold vs basal). In addition, 5HT induced a 
significant increase of total GluR1 expression that was not reversed by the 
investigated antagonists, suggesting that 5HT7, 5HT6, 5HT4 receptors were not 
involved in this latter effect. Moreover, the selective 5HT7 receptor agonist AS-
19 induced a significant increase of GluR1 phosphorylation (3.4±0.2 fold vs 
basal) that was reversed by SB258719 (1.1±0.2 fold vs basal). No effect was 
observed on total GluR1 expression.  Overall, this data suggest that 5HT 
increased GluR1 phosphorylation at Ser 845 and this modulation was mediated 
by 5HT7 receptors.    
 
Section 3.6.1 Influence of 5HT7 receptors on AMPAR trafficking 
 
One of the effects produced by GluR1phosphorylation at Ser 845 is a 
modulation of receptor trafficking. Recent studies suggested that GluR1 
phosphorylation at Ser 845 primes AMPAR for synaptic incorporation because it 
induces a transport of AMPA on the surface membrane of synapses (Gomes et 
al., 2004). In order to understand if the increase of GluR1 phosphorylation 
induced by 5HT7 receptors changed GluR1 expression in the plasma 
membrane, a biotinylation assay was performed. Basically, hippocampal 
neurons were treated with 5HT at different time points (5, 10 and 30 min) at 
37°C. After one wash with cold PBS, cells were treated with biotin, which is a 
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membrane-impermeable reagent that hence labels all proteins present at the 
cell surface. These proteins were then isolated by affinity chromatography on 
streptavidin columns followed by an analysis of membrane-associated GluR1 
and phosphorylated GluR1 at Ser 845.  Membranes-associated GluR1 was 
normalized for pan-Cadherine proteins which are a family of single chain 
glycoprotein receptors mediating calcium dependent cell-cell adhesion. They 
are expressed principally in the plasma membranes and then anti pan-
Cadherine antibodies are used as a specific plasma membrane marker (Geiger 
et al., 1990).    
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Figure 25 Effect of 5HT on surface phopshorylated GluR1 at Ser 842 and surface 
total GluR1. (a) Representative western blot of neurons treated with 1 µM 5HT at 
different time points.  Surface proteins were isolated using biotinylation assay as 
described in the methods. Extracts were analysed using anti-phosphorylated GluR1 at 
Ser845, anti-GluR1, anti-pan cadherine and anti-GAPDH antibodies. (b) Quantification 
of phosphorylated GluR1(Ser845) and total GluR1 in the total extract and in the surface 
fraction. Amount of proteins were normalised using GAPDH and pan-cadherine in the 
total extract and in the surface fraction respectively. Value are expressed as fold 
increase±SEM. respect to basal of three different experiments (n=3; One-way ANOVA, 
Dunnett’s test; *P<0.05 vs. Basal).  
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5HT produced a clear increase of phopshorylated GluR1 both in total extract 
and in surface fraction at all time points. This effect was already detectable at 5 
min after addition and was stable up to 30 min. In contrast, no difference in 
GluR1 expression was detected in both extracts, suggesting that GluR1 
phosphorylation induced by 5HT was not followed by a change of GluR1 
expression in the plasma membrane.    
Literature described that GluR1 phosphorylation at Ser845 is mediated by 
protein kinase A (PKA). which isnormalyc activated by an increase of 
intracellular cAMP. Further analysis had the aim to confirm if the increase of 
phopshorylated GluR1 at Ser845 was due to 5HT7 receptors through the 
activation of PKA.  Hippocampal neurons were treated with H89, a potent 
inhibitor of PKA, and SB259719 for 15 min before stimulation with 5HT for 5 min 
at 37°C.   Biotinylation assay and analysis of GluR1 phosphorylation were then 
performed as described before. 
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Figure X Effect of SB258719 and H89 on surface phopshorylated GluR1 at Ser 842. (a)  
Figure 26. Representative western blot of neurons treated with SB258719 and H89 
for 15 min followed by 1 µM 5HT treatment for 5 min. Surface proteins were isolated 
using biotinylation assay as described in the methods. (b) Quantification of 
phosphorylated GluR1(Ser845) in total extract and in surface fraction. Amount of 
proteins were normalised using GAPDH and pan-cadherine in the total extract in the 
surface fraction, respectively. Value are expressed as fold increase±SEM. with respect 
to basal of three different experiments (n=3; One-way ANOVA followed by post hoc 
comparisons (LSD method) Vs Basal or 5HT,*P<0.05 vs. Basal, #P<0.05 Vs 1 µM 
5HT;).  
 
5HT increased GluR1 phosphorylation in the surface fraction (8.1±0.8 vs. basal) 
and the effect was blocked by SB258719 (2.2±0.3 vs. basal) and H89 (0.9±0.3 
vs. basal). Similarly, a significant increase of phosphorylated GluR1 induced by 
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5HT in the total extract (7.1±0.4 vs. Basal) was reversed by SB258719 (2.0±0.3 
vs. Basal) and by H89 (1.0±0.4 vs. Basal). These results show that GluR1 
phosphorylation in plasma membranes of hippocampal neurons was mainly 
induced by 5HT7 receptors via PKA activation. 
 
Section 3.6.2 PDE4 and PDE10 regulate GluR1 phopshorylation induced by 
5HT7 receptors  
 
PDEs are a family of enzymes that control the degradation of intracellular cAMP 
and cGMP. They present specific subcellular compartmentalizations and 
modulate the signalling cascades triggered by these two molecules. Previous 
experiments demonstrated that activation of 5HT7 receptors in hippocampal 
neurons altered cAMP levels resulting in increased GluR1 phosphorylation. A 
further investigation was then performed to understand if PDE4 and PDE10 
may modulate GluR1 phosphorylation induced by 5HT7 receptors in 
hippocampal neurons, since these enzymes are expressed in the hippocampus 
of adult rat brain (Menniti et al., 2006). Neurons were treated with rolipram (10 
µM; PDE4 inhibitor) or papaverine (10 µM; PDE 10 inhibitor) for 30 min and 
then stimulated with 5HT (1 µM) for 5 min. 
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Figure 27 Effect of rolipram and papaverine on phopshorylated GluR1 at Ser 842 
and total GluR1. (a) Representative western blots of neurons treated for 30 min with 
10 µM Rolipram or 10 µM Papaverine followed by 1 µM 5HT treatment for 5 min. (b) 
Quantification of phosphorylated GluR1 and total GluR1. Ratio of 
GluR1(Ser845P)/GAPDH, totGluR1/GAPDH and GluR1(Ser845P)/totGluR1 are 
expressed as fold increase±SEM with respect to basal levels of three different 
experiments (n=3; One-way ANOVA followed by post hoc comparisons (LSD method) 
Vs Basal or 5HT,*P<0.05 vs. Basal,#P<0.05 Vs 1 µM 5HT (). 
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Rolipram, papaverine and 5HT significantly increased phosphorylated GluR1 of 
1.9±0.4, 4.0±0.3 and 13.3±1.8 folds compared to basal levels, respectively. Pre-
incubation with rolipram or papaverine potentiated 5HT-induced 
phosphorylation by 18.5±3.4 and 25.8±6.0 fold, respectively. Rolipram and 
papaverine did not show any effect on total GluR1 and the increase of total 
GluR1 induced by 5HT was not affected by PDE inhibitors. These data identify 
that PDE4 and PDE10 are actively involved in GluR1 phosphorylation induced 
by 5HT7 receptors in hippocampal neurons.    
 
Section 3.6.3 Influence of 5HT7 receptors on Ca
2+ intake mediated by 
AMPA  
 
AMPAR is a ionotropic transmembrane receptor activated by glutamate that 
controls cell permeability to calcium, sodium and potassium ions. PKA 
activation and consequent increase of GluR1 phosphorylation at Ser 845 could 
affect receptor trafficking and potentiate AMPA function (Oh MC et. al., 2006). 
To understand if GluR1 phosphorylation modulated by 5HT7 receptors affect 
physiological function of AMPAR, Ca2+ intake induced by AMPA was measured 
in hippocampal neurons after exposure to 5HT or FSK.  
Labelling was performed by incubating neurons with the Ca2+ indicator dye 
Fluo4 for 45 min at 37°C in HBSS buffer. Once labelled, cells were incubated 
with 10 µM 5HT or 10 µM FSK for 10 min at 37°C and then stimulated with 
increasing concentrations of AMPA (10 nM – 15  µM).    
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Figure 28. Effect of 5HT and FSK in [Ca2+]i influx induced by AMPA.  10 µM 5HT or 
10 µM FSK were added to cultured neurons for 10 min and then the increase of 
intracellular [Ca2+]i  induced by AMPA was measured with FLIPR TETRA ([Ca2+]i). Data 
are expressed as percentage of basal counts and represent the mean±SEM of at least 
three experiments (n=3). 
 
AMPA produced a concentration-dependent increase of Ca2+ with a pEC50 of 
6.14±0.05 which was not altered by 5HT (6.12±0.07) nor FSK (6.20±0.07). 
Similarly, maximal response to AMPA was not changed after the exposure to 
5HT or FSK (one-way ANOVA, Dunnett’s test).       
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Chapter 4 Discussion 
 
Section 4.1 Interaction between interleukin 1, p38 MAP kinase and SERT 
in native tissue and recombinant cell lines 
 
Available evidence supports the notion that an altered immune response may 
influence CNS function, resulting in the development of depressive illness 
(Raison at al., 2006). One of the mechanisms that may explain this link is that 
pro-inflammatory cytokines, elevated in depressed patients, have been shown 
to have a direct modulation of SERT function by p38 MAP kinase activation in 
vitro (Zhu et al., 2005, 2006). Mitogen-activated protein (MAP) kinases are 
serine/threonine-specific protein kinases which respond to extracellular stimuli 
and regulate various cellular activities, such as gene expression, mitosis, 
differentiation, and cell survival/apoptosis (Cuenda & Rousseau, 2007). The role 
of cytokines via p38 MAP kinase in the modulation of SERT has been 
demonstrated in mice synaptosomes, in rat embryonic raphe RN46A cells and 
in recombinant cells expressing human SERT. where  p38 MAP kinase may 
activate SERT by directly changing functional activity rather than expression 
levels. Such effects were reversed in the presence of the p38 MAP kinase 
selective inhibitor, SB203580, confirming that the regulation of neuronal SERT 
activity induced by cytokines is mediated by p38 MAP kinase linked pathways 
(Zhu et al., 2007). 
p38 MAP kinase belong to the MAPK superfamily and is activated by numerous 
cytokines as well as by environmental and chemical stressors in many cases 
triggering inflammatory and apoptotic pathways. Anisomycin, a protein 
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synthesis inhibitor derived from Streptomyces griseolus, induces an activation 
of p38 MAP kinase phosphorylation in a variety of cells including neutrophils 
(Nahas et al., 1996), mast cells (Zhang et al., 1997), and myocardial cells 
(Mcnicol, 1996). This p38 MAP kinase activation induced by anisomycin was 
followed by the activation of SERT in an SB203580-sensitive manner in 
recombinant cell line and in native tissue mimic the effect observed on SERT by 
cytokines (Zhu et. al. 2005). Other studies demonstrated that inhibition of p38 
MAP kinase by PD169316 or SB203580 reduced 5HT transport in rat midbrain 
synaptosomes and that the constitutive active form of MKK3b (upstream kinase 
that phosphorylates p38 MAP kinase) co-transfected with SERT in HEK-293 
cells increased the 5HT transport. Additionally, decreasing p38 MAP kinase 
expression by siRNAs in this recombinant HEK-293 reduced 5HT transport and 
surface SERT expression, indicating a basal SERT activity maintained by an 
constitutively active form of p38 MAP kinase (Samuvel et al., 2005).    
Based on what was reported in the literature, in the present studies rat and 
mouse cortical synaptosomes were treated with IL-1  and anisomycin at 
different concentrations and time points followed by a measurement of 5HT 
uptake. In contrast to literature reports, the current work has failed to see such 
effects in both rat and mouse synaptosomes irrespective of methodology and 
brain area used. Two possible hypothesis for this discrepancy were evaluated in 
mice brain synaptosomes in which literature reported this activation. The first 
involved animal housing that may induce sufficient stress to endogenously 
activate p38 MAP kinase thus masking the effects of IL-1  and anisomycin on 
5HT uptake. Therefore, further 5HT uptake studies were performed by using 
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brain synaptosomes from striatum and midbrain of individually-housed mice. 
Using these conditions, still no effect was observed, suggesting that there was 
no activation of SERT function by anisomycin irrespective to the housing 
conditions.   
On the other hand, it could be that the synaptosome preparation itself altered 
the activation of p38 MAP kinase. Literature has reported that the anisomycin 
effects in rat raphe cells and human platelets were more pronounced (~100 and 
~ 60% above basal) than those observed in mouse brain synaptosomes (~20% 
above basal), supporting the hypothesis that the mechanics of synaptosomal 
preparations may indeed alter the basal activity of p38 MAP kinase and hence 
limit the responsiveness to anisomycin (Zhu et al., 2007).   
In order to assess if the treatment with anisomycin was able to promote the 
change in the status of p38 MAP kinase from non active (non-phosphorylated) 
to active form (dual tyrosin-phosphorylated), synaptosomes were treated with 
IL-1β or anisomycin and then analysed by ELISA to quantify the phospho-MAP 
kinase in various samples. The data revealed that neither IL-1ß nor anisomycin 
could activate p38 MAP kinase in rat synaptosomes from cortex and striatum, 
while in a parallel experiment performed in HeLa cells, both compounds 
produced a large effect. These new findings suggested that in my synaptosome 
preparation, neither IL-1ß nor anisomycin have the capacity to induce p38 MAP 
kinase activation and consequently no downstream signal is produced that 
could act on transporter function. 
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Alternative biological systems in which SERT function was modulated by 
anisomycin in vitro were human blood platelets and rat basophilic leukemia cells 
RBL-2H3 (Zhu et al., 2005). Platelets treated with 1µM anisomycin for 10 min 
showed an increase of 5HT uptake which was reversed by the presence of p38 
MAP kinase inhibitor, SB203580. RBL-2H3 treated with 1µM anisomycin for 10 
min showed a reduction of SERT Km for 5HT (1057 ±145 versus 628 ±70µM, 
p<0.05) without a significant change in maximal transport capacity (Vmax). In 
order to understand if the reduction of Km reflected a change of 5HT affinity, the 
Ki of 5HT was estimated in the [125I]RTI-55 competitive binding assay in whole 
cell. Under this conditions, 1µM anisomycin incubated for 10 min reduced 
significantly the apparent 5HT Ki for [125I]RTI-55 (1.31 ± 0.26 µM in the vehicle 
control, 0.24 ± 0.005 µM in the presence of anisomycin, p<0.05) and this effect 
was blocked by SB203580. The study then supported the hypothesis that p38 
MAP kinase impacts SERT not by a change in surface trafficking but by a 
catalytic modulation of pre-existing surface-resident transporters. These 
findings were then used to set up an in vitro human blood platelet and RBL-2H3 
cell uptake assays to assess the effects of the p38 MAP kinase on 5HT uptake 
in a system perhaps less prone to mechanical and behavioural stress. In 
addition, anisomycin was also tested in LLC-PK cells expressing human 
recombinant SERT (hSERT-LLCPK). This cell line was used because the high 
expression of SERT could better highlight the possible interaction with p38 MAP 
kinase. In all these in vitro systems, anisomycin did not potentiate the SERT 
function, comparable to results observed in synaptosomes. The analysis of p38 
MAP kinase phosphorylation in the hSERT-LLCPK confirmed that anisomycin 
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induced an activation of p38 MAP kinase; nevertheless, a change of SERT 
function was not induced. The conditions used in these assays were identical to 
those used in the literature on RBL-2H3 cell line in which a change of SERT 
function was observed.  
Overall, the discrepancy between the literature and these results in the present 
thesis were not clarified although many approaches were used. SERT is likely 
to be phosphorylated on multiple domains and different kinase and 
phosphatase may act in concert at different steps in the trasporter’s life cycle to 
change the trafficking or the catalytic activity. The lack of effect of anisomycin in 
brain synaptosomes, platelets and cell lines could be then explained by the fact 
that crucial factors for the activation of p38 MAP kinase and its modulation on 
SERT are not present in these systems. 
 Moreover, p38 MAP kinase is regulated by stress and little changes of this 
status during sample manipulation could interfere with its activity. For these 
reasons an in vivo or ex vivo study could be more suitable to further explore this 
complex mechanism. However, the fact that p38 MAP kinase activation 
observed in hSERT-LLCPK did not produce a change of SERT function may 
suggest a different regulation of human SERT compared to rodents which may 
involve different secondary mediators other than p38 MAP kinase 
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Section 4.2 Infiammatory cytokines do not link with a regulation of 
serotonin transporter in rats treated with LPS  
 
In animal models, treatment with LPS can elicit a series of behavioural changes 
called “sickness behaviour” such as reduction of food intake and withdrawal 
from the physical and social environment. Sickness is an adaptive response to 
infection by pathogens and fully reversible once the pathogen has been cleared. 
Considering the temporal aspects of symptom expression, sickness behaviour 
develops rapidly after administration of LPS in animals and usually peaks 2–6 h 
post-treatment. These effects are always associated with an increase of plasma 
cytokines and then the activation of inflammatory response. Sickness behaviour 
gradually resolves after 6h but this high level of cytokines in the brain evolves 
into depressive-like behaviour 24h post-LPS (Dantzer et al., 2008, Capuron and 
Miller, 2011). The indications that depression-like behaviour remained after 
sickness behaviour came from experiments in which LPS-treated mice 
displayed increased immobility in the tail-suspension test and in the forced-
swim test 24 hours after treatment, a time point when motor activity had 
returned to normal (Frenois et al., 2007). The effect of cytokines on behaviour 
are similar to those showed by depressive patients such as anhedonia, fatigue, 
loss of energy and then this model, is often used to understand the link between 
cytokines and the pathophysiology of psychiatry disease. An expansive 
literature has proposed that cytokines can alter serotonergic neurotransmission 
in in vitro systems by the modulation of SERT function. However, a clear link 
between inflammation effectors and 5HT transporter activity in in vivo or ex vivo 
experiments was not well documented. Moreover, my previous in vitro 
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investigations showed no link between IL1β, p38 MAP kinase activation and 
SERT suggesting that a different approach had to be used to better understand 
this mechanism.  A  recent study reported that LPS induced a dose- and time-
dependent alteration in SERT activity, measured ex-vivo in synaptosomes from 
C57BL/6 (inbred) and CD-1 (outbred) mice (Zhu et al., 2010). This effect was 
similar across different brain areas (frontal cortex, hippocampus, striatum and 
midbrain) and then was not dependent on tissue used. Moreover, SERT 
stimulation by LPS induced depressive-like behaviours because it was 
paralleled by increased immobility in both the tail suspension test (TST) and the 
forced swim test (FST). The stimulation of SERT activity and induced immobility 
were absent when LPS was administered to interleukin-1 receptor (IL-1R)-
deficient mice and in the presence of SB203580. These data therefore 
confirmed that p38 MAP kinase and IL-1β receptors pathway are involved in the 
modulation of SERT and this caused a depressive-like behaviour in mice.    
The same ex vivo approach was used in this PhD study where LPS was 
injected directly into the rat brain and then, after two hours, SERT function was 
measured in parallel with cytokine levels. Although pro-inflammatory cytokines 
involved in the modulation of SERT, such as IL-1ß and TNFα, showed a 
significant increase, a modulation of SERT activity in term of Km and Vmax was 
not detected, confirming again that a signalling cascade induced by cytokines 
does not affect the rat SERT function in vitro and in vivo.   The results obtained 
using these different methodologies were quite unexpected because no effect 
on SERT was induced by the cytokines signalling pathways or p38 MAP kinase 
activation. These negative data can be explained by a potential influence of the 
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specific approaches chosen in this study, for example, the use of IL-1  as the 
reference cytokine in the modulation of SERT activity. This cytokine has an 
important role as mediator of the neurochemical alterations that occur in 
response to an immunological challenge (Dantzer et al 2006). Indeed, literature 
reported this direct modulation of SERT function (Zhu et al, 2005). However, 
clinical and preclinical evidence shows that other potential cytokines (IL-6, IL-2 
and IFN ) are important in the development of depressive-like symptoms and 
can modulate the level of some monoamines including 5HT (Song et al., 2002, 
La costa 2000, Anisman et al., 2007; Sato et al., 2006) Moreover, TNFα 
demonstrated a direct activation of SERT in a cell line (Mossner et al., 1998) 
and in mice synaptosomes (Zhu et al 2005).These findings suggest that IL-6, IL-
2, IFN  and TNFα may also modulate significantly serotonergic transmission in 
particular SERT function/expression. Another variable of this study was the 
brain regions (cortex, hippocampus and midbrain) in which the in vitro and in 
vivo study was conducted. They are relevant for many psychiatry diseases and 
monoamine transporters are highly expressed in these areas. Moreover, many 
effects following LPS or cytokines injection in animals were reported in these 
regions (Anisman et al., 2008, Hayley et al 2001). However, other regions may 
be more involved in the interaction with cytokines such as the basal ganglia. 
Basal ganglia and the subgenual and dorsal aspects of the anterior cingulate 
cortex (ACC) seem to be areas in which neurocircuits are affected by cytokines 
(Capuron et al., 2011). In particular, IFN  increased glucose metabolism in 
nasal ganglia and cerebellum while it was decreased in dorsal prefrontal cortex 
(Capuron et al., 2007). Dopamine neurons are present in basal ganglia 
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especially in striatum (Smith and kieval 2004) and p38 MAP kinase showed a 
direct interaction with the dopamine transporter (Zhu et. al, 2005) suggesting a 
possible modulation of the dopaminergic system induced by cytokines in basal 
ganglia. The time of treatment both in in vitro and ex vivo experiments could be 
another important variable that needs to be discussed. Many In vitro data 
suggest a time dependent-effect of cytokines and p38 MAP kinase activation on 
monoamine transporter function (Zhu et. al., 2005) Moreover, in animal models, 
the duration of treatment seems a key factor in the change of neurochemistry 
induced by cytokines administration. For example, this was reported for IFNα 
and IL-1  where acute vs chronic administrations showed a different changes of 
monoaminergic levels and their metabolites in mice brain (Sato et al., 2006; 
Anisman et al., 2008). LPS treatment performed in this PhD lasted two hours 
and this produced a big cytokine increase without effect on serotonin uptake. 
However, it may be that a longer incubation or chronic treatment with LPS 
induced long-lasting change of the serotonergic system including change of 
SERT expression and consequently modification of 5HT level in the brain.     
Despite the number of variables described above, the important finding 
emanating from this study is that the hypothesis in which cytokines alter the 
serotonergic system by modulation of SERT function through p38 MAP kinase 
was not confirmed and then this may be not a relevant mechanism in the 
pathology of depression induced by altered immune response. We 
demonstrated that direct activation of p38 MAP kinase or the stimulation of 
immune response in brain by LPS did not change the function or the expression 
of SERT. Serotonin is certainly connected with the effect of cytokines in the 
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alteration of brain function but probably 5HT participates more actively to the 
control of cytokines level which is the object of the second part of this PhD and 
will be discussed later (section 4.6). The hyphothesis describing the modulation 
of SERT and other monoamine transporters by cytokines lead to consideration 
of  the selective serotonin reuptake inhibitors (SSRI) such as fluoxetine as a 
potential therapy in the treatment of psychiatry diseases associated with the 
abnormal immune response. However, this hypothesis should be revisited since 
findings generated in this study did not confirm the interaction between 
cytokines, p38 MAP kinase and SERT. A mechanism that can suggest an 
alternative efficient therapy in the pathophysiology of depression induced by 
cytokines which is well supported by in vivo and in vitro study is the activity of 
cytokines on indoleamine 2,3-dioxygenease (IDO). This enzyme converts the 
main precursor of serotonin, tryptophan (TRP), into kynurenine (KYN) and it has 
been demonstrated to be activated by cytokines, reducing TRP availability and 
consequently decreasing 5HT concentrations in the brain. In parallel, a 
cytokine-induced augmentation of KYN increases the neurotoxic components 
that may also produce an increase in the NMDA receptor agonist quinolinic acid 
in the brain. A depletion of TRP along with an increase of quinolinic acid and 
consequently an altered glutamatergic neurotransmission are strongly 
associated with depression (Muller & Schwarz, 2007).  
Recently, literature reported that peripheral administration of LPS to mice led to 
increased expression of IDO in the brain along with IL-1β, TNFα, IFN  and this 
effect was associated with an evidence of sickness behaviours measured by 
increased duration of immobility in both the forced-swim and tail suspension 
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tests. This effect was abolished by the administration of 1MT, a competitive 
inhibitor of IDO that normalized IDO expression without changing the increase 
of cytokine levels. The increase of the level of kynurenic acid after LPS 
administration strongly suggested that the increased ratio between kynurenic 
acid and tryptophan rather than a change in tryptophan levels was involved in 
causing the sickness behaviour. This hypothesis was also confirmed by the 
finding that KYN injected in rat brain dose dependently caused depressive-like 
behaviour (O’Connor et al., 2008).    
A significant effect on TRP concentration was highlighted in patients with 
malignant melanoma treated with IFNα and IL-2 where TRP blood concentration 
significantly decreased during the therapy. This reduction was consistent with 
the development and intensity of mood and cognitive impairment symptoms 
(Capuron et al., 2002).  Moreover, clinical studies of patients with chronic 
hepatitis C (HCV) infection treated with IFN-α showed that in blood TRP 
availability was significantly reduced over the therapy although IFN-α had no 
effect on CSF TRP concentrations.. The concentration of KYN increased 
significantly and there was a correlation between the increasing level of KYN 
and the rise in the severity of depressive symptoms, suggesting that IDO 
activated by IFN-α is involved in the pathophysiology of depression changing 
TRP levels (Raison et al., 2010).   
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Section 4.3 Interaction between 5HT7 receptors and p38 MAP kinase in 
glial cells  
 
The neurotransmitter serotonin is involved in a number of processes through 
the central nervous system and this function is mediated by a large family of 
receptors. The 5HT7 receptor was the last addition to the large serotonin 
subfamily of G-protein coupled receptors. Considering the number of papers 
published in the serotonin receptor subtypes field, the 5HT7 receptor is not the 
most studied, being surpassed by 5HT1A, 5HT2A, 5HT3, and 5HT4 receptors. 
This might be explained by the lack for a long time period of selective 5HT7 
receptor ligands that would help researchers to understand the 
pathophysiological role of this receptor. Thus, since antagonists and, to some 
extent, agonists became available as well as 5HT7 receptor-knockout mice, our 
understanding of the role of the 5HT7 receptor in normal and pathological 
processes has improved. One of the mechanisms that has been recently 
described but is not still clear is the involvement of 5HT7 receptors in the 
inflammatory process and this effect on the CNS functions.  Previous 
investigations in primary rat hippocampal astrocytes treated with 5HT showed 
inductions of mRNA of IL-6 gene after 1 hour but the receptors subtypes 
involved were not explored in details (Pousset et al., 1996). The induction of IL-
6 synthesis by 5HT was shown also in human vascular smooth muscle cells (Ito 
et al., 2000). Finally, other investigations suggested that 5HT7 receptors 
regulate the release of IL-6 from astrocytoma and microglia via p38 MAP kinase 
(Lieb et al., 2005; Mahe et al., 2004).  
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Lieb et al. (2005) showed that astrocytoma U373 MG treated with 100nM 5HT 
for a period of 120 min showed a significant increase of phospho p38 MAP 
kinase with a maximal response at 10 min. The release of IL-6 induced by 5HT 
and the p38 MAP kinase activation was fully reversed by 10µM 5HT7 receptors 
antagonist SB202190 confirming the interaction between 5HT7 receptors and 
p38 MAP kinase in U373 MG cells. Experiments performed in this PhD study 
revealed that 5HT7 receptors were expressed in rat cortical astrocytes and were 
functionally coupled with an increase of intracellular cAMP. Moreover, serotonin 
via 5HT7 receptors increased the p38 MAP kinase phosphorylation after 5 min 
from stimulus confirming that the signalling cascade of 5HT7 receptors involved 
p38 MAP kinase activation. All these data confirmed the importance of 5HT7 
receptors in the regulation of serotonergic function in astrocytes and suggested 
an important role in the control of cytokine release through p38 MAP kinase.  
p38 MAP kinase is an important regulator of cytokine intracellular signals 
especially in those processes that induce interleukin release. p38α was first 
isolated as a 38-kDa protein rapidly tyrosine phosphorylated in response to LPS 
stimulation (Han et al., 1994). Four splice variants of the p38 MAP kinase family 
have been now identified: p38α, p38β, p38γ (ERK6, SAPK3) and p38δ (SAPK4) 
(Zarubin and Han, 2005). The ELISA used was not selective for a specific p38 
MAP kinase isoform and hence it is unknown which isoforms interact with 5HT7 
receptors. The biological consequence of p38 MAP kinase activation can be 
various because different kinases, transcription factors and gene expression are 
activated downstream of p38 MAP kinase. A strong link has been established 
between p38 MAP kinase pathway and apoptosis, control of cell cycle, 
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cardiomyocyte hypertrophy, development and cell differentiation (Zarubin and 
Han, 2005). However the principal pathway involved with p38 MAP kinase is 
inflammation. Rheumatoid arthritis, Alzheimer’s disease and inflammatory 
bowel disease are all postulated to be regulated in part by the p38 MAPK 
pathway (Johnson and Bailey, 2003; Hollenbach et al., 2004). The activation of 
the p38 MAPK pathway induces the production of proinflammatory cytokines 
(IL-1β, TNF-α and IL-6)(Salituro et al., 1999; Lee et al., 2000); induction of 
enzymes such as COX-2 (Badger et al., 1998); expression of intracellular 
enzymes such as iNOS, a regulator of oxidation (Da silva et al., 1997). In order 
to further confirm the role of 5HT7 receptors in the release of inflammatory 
factors in brain via p38 MAP kinase, studies are ongoing to determine the level 
of IL-6 in medium of cortical astrocytes after a stimulus with serotonin or AS19 
at different time points. These results will be the basis of further investigations 
to indentify which cytokines are secreted following the activation of 5HT7 
receptors in cortical astrocytes and the pathways involved such as PKA, PKC, 
Erk1.  
Little is known about the role of 5HT7 receptors in inflammatory events 
especially in the CNS system. Considering the influence of cytokines on 
neuronal transmission associated with behavioural changing, it can be 
speculated that the role of 5HT7 receptors in the regulation cytokines may be 
linked with the antidepressive effect of 5HT7 receptors antagonists in in vivo 
models. Further experiments would be focused to better understand if a 
treatment with 5HT7 receptor antagonists could therefore decrease the level of 
cytokines in the brain and then dampen the negative impact of inflammatory 
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events in brain function. Moreover, microglia cells, derived from peripheral 
macrophages, secrete Th1 cytokines such as IL-12, whereas astrocytes inhibit 
the production of IL-12 and other type 1 cytokines and secrete the Type 2 
cytokine IL-10. The type1/type2 imbalance in the CNS which could be caused 
by the imbalance in the activation of microglia and astrocytes, has already been 
observed in depression (Muller & Schwarz, 2007). 5HT7 antagonist could then 
have an effect in the balance of type1/tyep2 cytokines which is may be linked 
with depressive status.   
 
Section 4.4 Expression of 5HT7 receptors in hippocampal neurons which 
control the activation of CREB but not p38 MAP kinase    
 
Literature reports that a number of 5HT receptors subtypes that are positively 
coupled with adenylate cyclase, such as 5HT4 and 5HT6 and 5HT7 receptors, 
and these are expressed in hippocampus. The increase of cAMP induced by 
these 5HT receptors and the following signalling cascade may generally affect 
neuronal activity through a protein kinase activation, or change of gene 
expression. Previous studies revealed the expression of 5HT7 receptors in 
cortical astrocytes with a positive link with cAMP pathway and p38 MAK kinase.  
So far, no published data are available concerning the role of 5HT7 receptors in 
neurons and its possible interaction with inflammatory processes involving p38 
MAP kinase. 
 The study performed in this PhD thesis characterized the expression of Gs-
coupled 5HT receptors in primary cultured neurons, showing that the mRNAs 
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encoding for 5HT6, 5HT4, 5HT7 receptors are expressed in cortical and 
hippocampal neurons after one week in culture. However, further explorations 
revealed that cortical neurons did not respond to a treatment with 5HT, while 
hippocampal neurons showed a significant increase of cAMP levels with a 
pEC50 of 7.2±0.2. This value is in agreement with previous reports showing a  
5HT-induced cAMP increase with a potency of 6.68±0.08 in rat cultured 
astrocytes (Hirst  et al, 1997) and of 7.7±0.1 in guinea-pig hippocampal 
membranes (Thomas et al., 1999).  In order to better define which receptors 
were actively involved in mediating 5HT stimulation of adenylate cyclase in 
hippocampal neurons, different antagonists were tested. The selective 5HT6 
and 5HT4 receptors antagonists SB399885 (Mikami et al., 2008) and GR113808 
(Hirst  et al., 2006) did not antagonize the effect of 5HT, thus suggesting that 
neither 5HT4 nor 5HT6 receptors were involved. In contrast, 5HT7 receptor 
antagonist SB258719 completely blocked this response with a pIC50 of 
7.95±0.09. Moreover, a shift of 5HT response curve produced by SB258719 
confirmed a pKB value of 8.23±0.1 with a competitive antagonist profile. This 
compound was fully characterized in various assays both in recombinant cells 
and native tissue. In binding experiments on HEK293 expressing recombinant 
human 5HT7 receptors and in guinea-pig hippocampal membranes, affinity 
values of SB258719 were 7.5 (n=2) and 7.2±0.1 (n=3) respectively (Thomas et 
al.,1998 and 1999) In cAMP functional experiments, SB258719 reversed the 
5HT response with pKb of 7.57±0.08 and 7.21±0.12 and 7.2 ±0.1 at human, rat 
rand guinea-pig 5HT7 receptors respectively (Mahe et al., 2004, Thomas et al., 
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1999).  All these data are in line with those obtained in this study, confirming the 
functional expression of 5HT7 receptors in hippocampal neurons. 
 All these data confirmed the expression of 5HT7 receptors in hippocampal 
neurons while 5HT6 and 5HT4 receptors do not appear to contribute to the 
cAMP signalling under these conditions. In this study, PCR primers did not 
discriminate the splice variants and therefore it is uncertain which 5HT7 
isoforms are expressed which could have a different interaction with adenylate 
cyclase.  The lack of 5HT response in cortical neurons could be explained by 
two reasons: the absence of Gs-coupled 5HT receptors expression in 
membranes under these conditions or the presence of Gi-coupled 5HT 
receptors that are negatively associated with adenylate cyclise balancing out an 
overall response. The lacks of selective agonists for the different classes of 5HT 
receptors complicate this analysis. However, the use of uncoupling agents such 
pertussis toxin (PTX) that blocks the responses mediated by protein Gi or 
selective antagonists for the different families of 5HT receptors, for example 
5HT1 receptor antagonists,  may help to explore these hypotheses.     
In the attempt to understand the events downstream of 5HT stimulation, CREB 
and p38 MAP kinase phosphorylation were also measured. These experiments 
revealed an increase of phosphoCREB[133] induced by 5HT with a maximal 
effect  5 min after stimulation. The 5HT7 receptor antagonist, SB258719 
significantly inhibited this response, confirming that 5HT7 receptors not only 
activated adenylate cyclase but were also directly involved in the 
phosphorylation of CREB[133]. This data confirmed the role of 5HT7 receptors 
in the regulation of CREB phosphorylation in hippocampal neurons (Mahgoub et 
120 
 
al., 2006). It can be noted that 10 µM SB258719 did not block completely the 
increase of CREB suggesting the presence of secondary signalling pathways 
activated by 5HT that are not inhibited by SB258719. In contrast, p38 MAP 
kinase was not affected by 5HT7 receptors stimulation over a period of 60 min. 
All these findings generated by using pharmacological and biochemical tools 
demonstrated that 5HT7 receptors regulate cAMP signalling in hippocampus 
with a modulation of CREB function. Increasing CREB phsphorylation and then 
its activation would be expected to alter the expression of specific target genes. 
Among the many potential target genes regulated by CREB are those for brain-
derived neurotrophic factor (BDNF) and its receptor, TrkB (Duman et al.,1995, 
Condorelli et al., 1994). Taking into account these findings, it would be 
interesting to understand if serotonin via 5HT7 receptors alters the levels of 
BDNF and TrkB in hippocampus.  
The analysis of p38 MAP kinase phosphorylation after the activation of 5HT7 
receptors revealed lack of activation of this kinase in neurons over a period of 
60 min.  This was in contrast with those reported in astrocyte and astrocytoma 
cells that showed an activation of p38 MAP kinase 5 min after 5HT addition.  
Status of p38 MAP kinase was also unchanged  using forskolin suggesting that 
an increase of cAMP was not an upstream signal for p38 MAP kinase activation 
in neurons. These data suggested that in both neurons and glia cells 5HT7 
receptors couple with an increase of intracellular cAMP and activation of CREB, 
whereas  the activation of 5HT7 receptors induced an activation of p38 MAP 
kinase only in glial cells and not in neurons. As described before, p38 MAP 
kinase exists in different isoforms and their activation can be specifically 
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controlled through different regulators and coactivated by various combinations 
of upstream regulators. In addition, the activation mechanisms of p38 MAP 
kinase may vary in different cells under various physiological or pathological 
conditions (Zarubin and Han., 2005). For this reason, it is complex to 
understand why in neurons p38 MAP kinase is not influenced by 5HT7 
receptors. However, it may be hypothesized that neurons and glial cells express 
different cofactors that specifically link 5HT7 receptors with the activation of p38 
MAP kinase. Finally, this work highlighted a different cell signalling of 5HT7 
receptors in the CNS between glial cells and neurons.    
 
Section 4.5 Serotonin induced a post-transcriptional modulation of AMPA 
receptors by 5HT7 receptors  
 
The previous studies reported the expression of 5HT7 receptors in neurons and 
that their activation results in accumulation of intracellular cAMP and activation 
of CREB.  The present study investigated also the interaction between 5HT7 
receptors and AMPA receptors (AMPAR). 5HT7 receptors are involved in the 
synaptic transmission regulating the neuronal excitability and LTP in 
hippocampus (Roberts et al., 2004).  Synaptic strength is tightly regulated by 
mechanisms that include a change in AMPA receptor (AMPAR) phosphorylation 
and their cellular distribution (Santos et al., 2009).    
Phosphorylation of AMPAR occurs at three serine residues located in the 
intracellular C-terminus: serine 831 (ser831) can be phosphorylated by protein 
kinase C (PKC), and CaMKII; serine 845 (ser845) is a protein kinase A (PKA) 
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and cGMP-dependent protein kinase II phosphorylation site and serine 818 
(ser818) is a substrate for PKC. Both Ser831 and Ser845 are important signals 
to deliver AMPARs into synapses and then determine the duration of synaptic 
activity. LTP induction increases the CaMKII-dependent phosphorylation of 
GluR1 at Ser831 (Mammen et al., 1997). However, mutation on GluR1-Ser831 
that prevented this phosphorylation, did not change the delivery of the receptor 
to synapses by active CaMKII (Hayashi et al., 2000). In contrast, mutation of 
Ser845 prevented the delivery of GluR1 to synapses (Esteban et al., 2003a) 
suggesting that Ser845 is critical for the delivery of AMPAR into synapses. In 
hippocampal neurons, I did not demonstrate a direct activation of PKA by 5HT7 
receptors but cAMP increase and the following CREB phosphorylation observed 
after the stimulus suggested that PKA could be activated as well by 5HT7 
receptors. This activation may trigger the Ser845 phosphorylation on AMPAR 
and then induce a change of AMPAR trafficking or expression which may be 
important for the control of neuronal plasticity in hippocampus. This study 
revealed that 5HT and AS-19 increased GluR1 phosphorylation at PKA site 
(Ser845) of about 12 and 3.5 folds respectively.  These levels of activity 
reflected the intrinsic activity of these agonists established in the cAMP assay, 
suggesting a direct correlation between the level of cAMP and GluR1 
phosphorylation. These effects were reversed by SB258719 but not by 
SB399885 and GR113808, confirming the involvement of 5HT7 receptors. The 
total GluR1 expression was also increased by 5HT but the above antagonists 
did not reverse this effect, suggesting that 5HT7, 5HT6 and 5HT4 were not 
involved. To the best of our knowledge this study was the first to demonstrate 
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an activation of GluR1 phosphorylation by 5HT7 receptors. Time course 
revealed that the GluR1 phosphorylation was maximal after just 5 min and 
remained at this level up to 30 min. The duration and onset of phosphorylation 
is regulated by the kind of kinase and phosphatase which are carried close to 
the effectors when receptors are activated.  Previous work showed that 5HT7 
receptors increased CREB phosphorylation in hippocampal neurons but these 
effects lasted maximum 5 min from stimulation. The different duration observed 
in the increase of GluR1 phosphorylation compared to CREB phopshorylation 
may suggests that 5HT7 receptors activate different kinase or phosphatase 
pathways specific for CREB or GluR1. The functional role of Ser 845 
phosphorylation has not been fully understood although studies from literature 
hypothesized a specific mechanism by which phosphorylation of ser845 should 
increase AMPAR in the synaptic site which is important for the control of LTP 
(Wang et al., 2005).  Basically, under basal conditions, GluR1 is expressed in 
the internal pools and on the surface membranes of neurons. The amplitude of 
synaptic potentiation is regulated by the distribution of these receptors that shift 
from the extrasynaptic to synaptic region during neuronal transmission 
(Passafaro et al., 2001). Ser845 phosphorylation induces an increase of surface 
GluR1 in the extrasynaptic AMPAR and then modulates the synaptic plasticity 
by regulating the pool of AMPARs available for synaptic incorporation (Oh et al., 
2006). GluR1 phosphorylation was induced by D1 dopamine receptors which 
are coupled with AC. D1 receptor agonist increases GluR1 phosphorylation at 
the protein kinase A phosphorylation site (Ser845) in nucleus accumbens cell 
cultures (Chao et al., 2002), and cultured hippocampal neurons (Gao et al., 
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2006). Moreover, a D1 receptor agonist on hippocampal pyramidal neurons 
accelerates AMPAR externalization in extrasynaptic sites through a pathway 
that depends mainly on PKA but also involves CaMKII (Gao et al., 2006). The 
effect of D1-PKA pathway on AMPAR trafficking plays an important role in the 
modulation of long-term synaptic changes observed in rats and in mice by 
dopamine (Huang et al.,2004). Based on these findings, further studies were 
designed to understand if 5HT7 receptors may mimic the effect of D1 receptors 
in hippocampus to control AMPA trafficking. After the stimulation with 5HT, 
proteins expressed on the surface of neurons were isolated and analysed by 
western blot. Results showed a significant increase of GluR1 phosphorylation in 
the surface pool while expression of total surface GluR1 was not altered. 
Moreover, the increase of surface GluR1 phosphorylation induced by 5HT was 
reversed by SB258719 and H89 confirming the involvement of 5HT7 receptors 
through the activation of PKA. These data then showed that 5HT7 receptors 
activate GluR1 phosphorylation at Ser845 in the surface pool via PKA without 
inducing GluR1 migration to the plasma membrane. The impact of this 
phosphorylation on AMPAR function in hippocampus remains to be explored 
since it did not seem to have an apparent effect on AMPAR trafficking. 
However, it may have an effect on AMPAR function determining a change of 
synaptic plasticity. This is better discussed in the section 4.5.2.   
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Section 4.5.1. PDE4 and PDE10 potentiate the effect of 5HT7 receptors on 
AMPAR in hippocampal neurons  
 
Activation of adenylate cyclase and following accumulation of cAMP takes place 
in specific microdomains in the cells. These microdomains are created by 
physical interaction between different components of these signal cascade and 
structural elements of the cells. PDEs are a family of enzymes that degrade the 
cAMP and cGMP and dampen quickly the signal cascades induced by cAMP or 
cGMP as second messengers. PDE participate in the regulation of temporal 
and spatial dimension of these microdomains because they are sequestered 
and anchored to sites near the receptors that trigger the signal cascade. PDE’s 
expression in the brain is tightly regulated and it is distributed in many regions 
where serotonin is present, such as hippocampus and cortex (Menniti et al., 
2006). PDE4 is the principal family involved in the degradation of cAMP 
throughout the body (Houslay et al., 2003). In the CNS, PDE4 is expressed in 
striatum, cortex and hippocampus within soluble intracellular compartments 
(Perez-Torrez et al., 2000).  Studies aimed to understand the physiological role 
of PDE4 described that, in hippocampus, it regulates the increase of CREB 
phosphorylation (Monti et al., 2006) and facilitate the induction of LTP (Barad et 
al., 1998). PDE10 enables to metabolize cAMP and cGMP and it is bound to the 
membranes (Menniti et al., 2006). It is expressed principally in striatum but is 
also present at low density in extrastriatal neurons, including those of the cortex 
and hippocampus (Seeger et. al., 2003). Further studies confirmed the 
expression of PDE4 and PDE10 in hippocampus where the chronic 
administration of rolipram (PDE4 inhibitor) and papaverine (PDE10 inhibitor) 
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increased CREB mRNA levels suggesting a role in the modulation of cAMP 
cascade. Moreover, a co-administration of rolipram with the 5HT reuptake 
inhibitor, imipramine induced a more rapid increase of CREB than either 
treatment alone suggesting an interaction between PDE and serotonergic 
system (Nibuya et al., 1996). However, the molecular mechanism that 
described the interaction between PDEs and serotonergic system and the 
functional significance in hippocampus were not clearly described. The present 
studies had the aim to understand if 5HT7 receptors expressed in hippocampal 
neurons interact with PDE4 and PDE10 in the regulation of GluR1 
phosphorylation. Experiments showed that rolipram and papaverine increased 
the level of GluR1 phosphorylation and when they were co-incubated with 5HT 
there was a significant potentiation of 5HT response. This study revealed 
therefore a positive interaction between PDE4 and PDE10 with 5HT7 receptors 
in hippocampus.  
Considering the key role of PDE4 and PDE10 in the modulation of cellular 
signalling pathway in the brain, they are a target for many CNS diseases. In 
particular PDE4 participates actively to cognitive process such as long-term 
memory formation, attention and executive function while there are some 
indications for the use of PDE10A inhibitors for the treatment of schizophrenia 
(Menniti et al., 2006). Increasing evidence suggests a role of PDE4 in 
depression since rolipram showed an antidepressant effect in humans (Zeller, 
1984). Subsequent work in preclinical models suggests that the antidepressant 
effects of PDE4 inhibition results from an up-regulation of brain-derived 
neurotrophic factor (BDNF) and the subsequent facilitation of neurogenesis in 
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the hippocampus (Nakagawa et al., 2002). However, this PhD study suggested 
that behavioural effects induced in in vivo by PDE4 and PDE10 inhibitors may 
result in part by an increase in 5HT7 receptor function in hippocampus.  
 
Section 4.5.2. Physiological effect of Ser845 phopshorylation induced by 
5HT7 receptors on AMPAR function   
 
The physiological impact of AMPAR phosphorylation induced by 5HT7 receptors 
on hippocRl neurons remains to be explored. Moreover, a recent publication 
reported that Ser845 phosphorylation on AMPAR induced by D1 receptors 
changed the AMPA current and channel open probability in spinal motoneurons 
using a whole-cell patch clamp techniques (Han and Whelan, 2009). This 
mechanism was independent of AMPAR mobilization because these effects 
were not blocked by the use of botulinum toxin C which is a blocker of receptor 
insertion. Moreover, inhibiting PKA with H89 completely abolished the effect of 
D1 agonist, which confirmed the involvement of PKA in the effect of D1 
receptors stimulation on AMPAR current (Han and Whelan., 2009). The 
physiological effect of PKA phosphorylation on AMPAR was previously 
investigated in transiently transfected HEK-293 cells with human GluR1 using 
whole-cell patch clamp recording techniques. Perfusion of glutamate onto the 
transfected HEK-293 cells resulted in the rapid activation of inward current that 
desensitized in the continuous presence of agonist. Once stable baseline 
recordings was obtained, purified PKA was perfused into the recording pipette. 
This intracellular perfusion of PKA resulted in 40% potentiation of the peak 
amplitude of the whole cell glutamate-gated current. This potentiation 
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developed over 15 min after introduction of PKA into the pipette and remained 
stable for the duration of the recording. No change in the rate of desensitization 
or in the steady state response was seen following the addition of PKA. These 
findings suggest that PKA phosphorylation may modulate not only AMPAR 
trafficking but also AMPAR function.  Hence, it can be speculated that 
phosphorylation induced by 5HT7 receptors act on AMPAR conductance rather 
than effecting AMPAR trafficking. AMPAR is an ionotropic glutamate receptor 
allowing the passage of sodium and potassium. The AMPAR also is permeable 
to calcium (Ca2+) and hence regulates Ca2+ influx into neurons. This is the 
mechanism responsible for the NMDA receptor-indipendent long term 
potentiation in  amygdala (Mahanty and Sah, 1998) and hippocampus 
(Feldmeyer et al., 1999). An assay that allows measurement of Ca2+ influx 
mediated by AMPAR uses a fluorometric imaging plate reader (FLIPR)/Ca2+ 
assay. I developed a FLIPR/Ca2+ assay on cultured hippocampal neurons with 
the aim to measure the effect of AMPA on Ca2+ influx and then understand if 
5HT via 5HT7 receptors influences this activity.  In parallel, FSK was also tested 
on Ca2+ influx evoked by AMPA because FSK showed a stronger GluR1 
phosphorylation compared to 5HT and hence an effect on AMPAR function may 
be more evident. AMPA showed a concentration dependent increase in Ca2+ 
influx with a pEC50 of 6.14±0.05. Neither 5HT nor FSK changed significantly the 
pEC50 of AMPA or the maximal AMPA response suggesting that although the 
activation of 5HT7 receptors changed AMPAR phosphorylation, it did not have a 
specific effects on Ca2+ influx evoked by AMPA under the current assay 
conditions.  
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A different approach should be used to better understand the impact of 5HT7 
receptors activation on AMPAR function.  One possible method could be the 
use of a whole-cell patch clamp techniques that allows the fine measurement of 
AMPAR current in hippocampal neurons in the presence of 5HT7 receptor 
agonist or antagonist. However, it cannot be excluded that the effect of 5HT7 
receptors on AMPAR function may require the involvement of additional signals 
such as the phoshorylation of Ser818 by PKC or Ser831 by CaMKII (Santos et 
al., 2009).  
 
Section 4.6.  Different functions of serotonin in hippocampus: 
neuroinflammation and synaptic plasticity.  
 
 The hypothesis of the interaction between inflammation and serotonergic 
transmission has been long discussed but the mechanism involved in this 
complex pathway has not been well clarified yet. The role of p38 MAP kinase 
and cytokines in the modulation of SERT function for the control of serotonin 
level was not supported by this study. Instead, important findings have been 
generated that confirmed the hypothesis of the influence of serotonin on p38 
MAP kinase function in primary astrocytes via  5HT7 receptor activation. This 
activation is principally mediated by an increase of intracellular cAMP which 
determined a direct activation of PKA. Previous studies in mouse embryonic 
fibroblasts, NIH 3T3, showed that PKA represented the predominant pathway 
after cAMP increase and p38 MAP kinase becomes activated by PKA in the 
activation of CREB (Delghandi et al., 2005). These findings suggested that PKA 
may mediate p38 MAP kinase and then participate in the control of serotonin-
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dependent cytokines release in primary astrocyte. The pathway suggested is: 
5HT7 receptors cAMP PKA p38 MAP kinase cytokines release. This 
mechanism then suggests that 5HT7 antagonists may work as anti-inflammatory 
drugs and may contrast the negative effects of abnormal regulation of the 
immune response on behavior. There are many data that suggest that  anti-
inflammatory drugs have a positive impact on antidepressive therapy. For 
example the COX-2 inhibitor, celecoxib, increased significantly the 
antidepressant efficacy of the norepinephrine reuptake inhibitor, reboxetine 
(Muller et al., 2006). This study then suggested that 5HT7 antagonists alone or 
in combination with  antidepressives may dampen the immune response in the 
brain and finally ameliorate depressive symptoms associated with inflammation. 
The influence of p38 MAP activation induced by 5HT7 receptors may be also 
connected with the serotonin synthesis, since a report showed an increase of 
p38 MAP kinase activity was associated with  decreased cerebrospinal fluid 
(CSF) concentrations of the serotonin metabolite, 5-HIAA, in early life stress of 
juvenile rhesus monkeys (Sanchez et al., 2007). 5HT7 receptor antagonists may 
block the p38 MAP kinase activation induced by cytokines to prevent  the 
decrease of serotonin levels.  
Not only microglia and macroglia but also neuronal cells release cytokines 
(Bergamaschi et al., 2006). However, 5HT7 receptors expressed in hippocampal 
neurons did not induce  p38 MAP kinase activation suggesting no control of 
cytokines release from neurons. Instead, this study highlighted a different role of 
5HT7 receptors in neurons which was associated to a modulation of GluR1 
phosphorylation at Ser845 with the contribution of PKA, PDE4 and PDE10. The 
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pathway suggested then is: 5HT7 receptors cAMP PKA GluR1[Ser831]. 
Despite, this, the study did not demonstrate clearly an altered expression of 
AMPAR induced by  5HT7 receptors, so it can be speculated that GluR1 
phosphorylation may increase the presence of AMPAR at the synaptic level and 
then modulate  synaptic plasticity. Since PDE4 and PDE10 are involved in this 
mechanism, this effect can be potentiated by the use of specific PDE4 or PDE10 
inhibitors such as Rolipram. Manipulating synaptic AMPAR trafficking has 
significant effect on learning, memory and drug addiction (Kessels and Malinow, 
2009) and a dysfunction of the regulation of extracellular glutamate levels has 
been implicated in a number of neurological and psychiatric diseases including 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, schizophrenia, 
obsessive-compulsive disorder, and mood disorders (major depressive 
disorders and bipolar disorder) (Zarate and Manji et al., 2008). Moreover, 
chronic therapy with antidepressives showed an increase of AMPA expression 
in neurons (Martinez-Turrillas et al., 2002) and positive AMPA modulators has 
been suggested as an effective treatment for major depression. There is not a 
clear mechanism explaining why positive AMPA modulators may be useful in 
depression although they should slow the desensitization and/or deactivation of 
AMPA in the presence of an agonist (Hashimoto 2009). Finally,  a hypothesis 
can be formulated that 5HT7 receptor agonists increase AMPA receptor 
phosphorylation thus increasing the glutamatergic neurotransmission mediated 
by AMPAR at the synaptic level and this can be beneficial for neurocognitive 
disorders involving the glutamatergic response. However, it can not be excluded 
that an exaggerated stimulation of AMPAR can produce also an excessive 
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glutamate response which may induce the development of cytotoxicity via 
NMDA or non-NMDA receptors as suggested by literature (Larm et al., 1997). 
Overall, further investigations need to be performed to better understand the 
potentiality of 5HT7 receptors as novel targets for neuropsychiatric disorders.    
 
Section 4.6. Conclusion 
 
The present study had the principal aim to demonstrate the molecular 
interaction between some mediators of inflammation (cytokines and p38 MAP 
kinase) with the serotonergic system in vitro and in vivo. Two different pathways 
were investigated: SERT modulation induced by cytokines and the role of 5HT7 
receptors in the control of cytokines release via p38 MAP kinase. The present 
study demonstrated that incubation with IL-1β or the activation of p38 MAP 
kinase did not have any effect on 5HT uptake in rodent native brain tissue 
(cortex, midbrain and striatum), in human platelets and in cell lines, in contrast 
to literature reports (Zhu et al., 2010). The lack of effect may be due to the 
absence of key factors for the activation of p38 MAP kinase in these systems 
and the consequent modulation on SERT. For this reason a different approach 
was then used in which a release of cytokines was induced directly in the rat 
brain through an i.c.v. LPS treatment followed by the analysis of SERT function. 
Although pro-inflammatory cytokines are involved in the change of animal mood 
such as IL-1ß and TNFα and displayed a significant increase in cortex and 
striatum, a modulation of SERT activity in term of Km and Vmax was not 
detected, confirming again that no interaction between cytokines, p38 MAP 
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kinase and SERT function in vitro nor in vivo was evident. However, this study 
revealed a positive interaction between 5HT7 receptors and p38 MAP kinase in 
glial cells supporting the role of 5HT via 5HT7 receptors in the regulation of 
cytokines release in the brain. However, this pathway was not present in 
hippocampal neurons where 5HT7 receptors did not activate p38 MAP kinase 
but instead increased the AMPAR and CREB phosphorylation at PKA 
dependent phosphorylation sites. The effect on AMPAR was reversed by the 
specific 5HT7 antagonist, SB258719 and PKA inhibitor, H89, confirming the 
specificity of response for 5HT7 receptors and the involvement of PKA in the 
mediation of AMPAR phosphorylation.  PDE4 and PDE10, which are expressed 
in hippocampus, impact 5HT7 receptors functions since their specific inhibition 
potentiated the effect of 5HT on AMPAR phosphorylation. Further experiments 
highlighted that 5HT7 receptors changed the surface AMPAR phosphorylation 
without a specific effects on Ca2+ influx evoked via AMPAR.  Noteworthy, this is 
the first report that showed a positive interaction between 5HT7 receptors and 
AMPAR which will hopefully stimulates new investigations concerning the role 
of 5HT7 receptors in neuronal plasticity.  
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